Mutations and gene amplifications in Endometrial Carcinomas. “Clinical characteristics and potential targets for therapy related to KRAS, MYC, ATAD2, PIK3CA and FGFR2 alterations” by Birkeland, Even
Mutations and gene amplifications in 
Endometrial Carcinomas 
 
“Clinical characteristics and potential targets for therapy related to KRAS, 
MYC, ATAD2, PIK3CA and FGFR2 alterations”  
 
 
 
Even Birkeland 
 
 
 
 
 
 
 
 
 
 
Dissertation for the degree of philosophiae doctor (PhD) 
 
University of Bergen, Norway 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC ENVIRONMENT 
 
The PhD project has been conducted as part of the Gynaecologic Cancer 
Research Group directed by Professor Helga B. Salvesen as main supervisor 
and PhD Camilla Krakstad as co-supervisor. 
 
Translational research in gynaecological cancer has a long tradition at the 
Department of Obstetrics and Gynaecology, Haukeland University Hospital 
and the Department of Clinical Science, University of Bergen. Over the last 
three decades, several biobanks from gynaecologic malignancies have 
systematically been built and linked to clinical data at the Department. Since 
2001, fresh frozen tumour and blood samples from consented women treated 
for suspected gynaecologic cancers have been prospectively collected at our 
institution and in a multicenter setting (MoMaTEC). The goal is to explore 
potential biomarkers to improve and individualize treatment for patients with 
gynaecologic cancers. 
 
Around 20 members including research fellows, postdocs, students and 
technicians work in the research group. Five PhD-theses have been completed, 
8 post doc projects and 9 PhD projects are presently affiliated. 
 
Several international collaborators are also working together with the group, 
amongst them Professors Matthew Meyerson and Rameen Beroukhim, Harvard 
Medical School, Dana Farber Cancer Institute, Boston, USA and Professor 
Ronald Simon, Department of Pathology, University Medical Center Hamburg 
Eppendorf, Hamburg, Germany. The latter hosted Even Birkeland for 2 months 
to train in FISH analyses in 2010. Professor Karl-Henning Kalland at 
Department of Clinical Medicine, University of Bergen collaborate in 
microarray studies.  
 
Main funding sources are the Norwegian Research Council and Norwegian 
Cancer Society (Harald Andersens legat), the University of Bergen and Helse 
Vest.  
 
 
 
ACKNOWLEDGEMENTS 
 
This work was conducted at the Department of Clinical Science, Section for 
Obstetrics and Gynecology at the University of Bergen. The study was 
supported by grants from the Norwegian Research Council (2010-2013)   
 
I want to thank my supervisor professor Helga Salvesen for introducing me to 
the field of clinical medicine, and to have opened up a new dimension of how 
to look at cancer research. I greatly appreciate her patience with a rather 
stubborn biologist, and for keeping me focused on the translational path not 
diving to deep into protein-protein interactions and post-translational 
modifications.  
 
Camilla Krakstad, my co-supervisor, her dedication and locomotive attitude to 
cancer research has been invaluable. Without her the thesis wagon would not 
have reached the station. 
 
Maria Ræder, without her technical skills regarding gene signatures I would be 
lost in web of transcriptional data, your efforts have been essential for my 
thesis.  
 
I want to thank my co-authors Danila Seidel, Kanthida Kusonmano, Kjell 
Petersen, Siv Mjøs, Erling A. Hoivik, Elisabeth Wik, Mari Kyllesø Halle, Anne 
M. Øyan, Karl-Henning Kalland, Henrica Maria Johanna Werner, Jone Trovik, 
Lars Akslen, Ronald Simon, Frederik Holst, Shyemaa Shehata, Steven 
Schumacher, Travis I. Zack, Antje Krohn, Susan E. Moody, Ingunn M. 
Stefansson, Pablo Tamayo, Jill P. Mesirov, and Rameen Beroukhim for their 
important contributions to my papers. 
 
 
A special thanks to Ellen Valen, for introducing me to the daily routines in the 
clinic and without you the mornings would be unbearable, without fresh coffee. 
Britt Edvardsen you are the cornerstone of our bio bank, without you I would 
still be digging around in the freezer for tissue specimens. 
 
I would like to thank Kristin Dahl Michelsen, Kjersti Mangseth and Olav 
Vintermyr for providing me with protocols regarding KRAS sequencing.  
 
All members of the Mohn lab, thank you for providing an excellent work 
environment and help in dark times when PCR machines tried to take over the 
world.  
 
A special thanks to Ronald Simon, Frederik Holst and Antje Krohn, for making 
me feel like home with a warm welcome to Hamburg, without you I could 
never have conducted the FISH experiments.  
 
Elisabeth Wik, office roommate and dear colleague, thank you for being a 
patient discussion partner and teaching me all I know about statistics, without 
your expertise, wisdom and sense of humour office life would have been much 
poorer. 
 
Erling Høyvik, office roommate, for your skilled contributions regarding 
sequencing and general good advice, I am truly grateful, and also for bringing 
in some masculinity in a highly feminine work environment.  
 
Kanthida Kusonmano, office roommate, for helping me with the troubles of 
bioinformatics.  
 
Siv Mjøs, your attitude towards medical science has been a refreshing 
experience, and I have learned a lot for you.  
 
 
I would also like to thank Mari Halle, Ingvild Løberg Tangen, Hilde Engerud, 
Anna Berg, Karen Mauland, Kadri Madissoo, Therese Bredholdt, Erica 
Werner, Marianne Høgetveit Myhren and Jone Trovik for providing a superb 
work environment.   
 
Also a thank to the clinical staff at the Section for Gynaecologic Oncology at 
Haukeland University Hospital, for providing high quality specimens and 
clinical data critical for this study.  
 
Lillian Hallseth, Bendik Nordanger, Tormund Njølstad and Hua My Hoang are 
thanked for providing excellent technical assistance. 
 
I would like to thank heads of the Department of Clinical Science, University 
of Bergen, and Department of Obstetrics and Gynecology, for securing 
excellent working conditions.  
 
Solveig, you have patiently supported me through this entire process, and I 
can’t describe how grateful I am to be with you. Lovise, my little bundle of 
sunshine, you have made my life into a rollercoaster of joy.  
 
 
 
ABBREVIATIONS 
AKT v-AKT murine thymoma viral oncogene homolog 
ATAD2 ATPase family, AAA domain containing 2 
BER Base excision repair 
BRAF v-raf murine sarcoma viral oncogene homolog B1  
cDNA Complementary deoxy nucleic acid 
CI  Confidence Interval 
CN Copy number 
CT       X-ray computed tomography 
DNA Deoxyribonucleic acid 
EC  Endometrioid endometrial cancer 
ECM Extra cellular matrix 
EGFR Epidermal growth factor receptor 
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog2, 
HER2  
Elk 1 ELK1, member of ETS oncogene family  
ERK1/2 Extra cellular regulated kinase 1/2  
ER-α. Oestrogen-receptor alpha  
ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 
FDR False discovery rate   
FFPE Formalin fixed, paraffin embedded 
FFT Fresh frozen tissue 
FGFR2 fibroblast growth factor receptor 
FIGO International Federation of Gynecology and Obstetrics 
FISH Fluorescent in situ hybridization 
GAP GTPase activating proteins 
GDP   Guanine di-phosphate 
GTP Guanine tri-phosphate 
GRB2 Growth factor receptor bound protein 2  
H&E Hematoxylin and eosin 
HNPCC Hereditary non-polyposis colorectal cancer 
 
HR  Hazard ratio 
HSP90 Heat shock protein 90 
IGF-1 Insulin growth factor-I 
IHC Immunohistochemistry 
IRS-1 Insulin receptor substrate 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
LOH Loss of heterozygosity 
MEK Mitogen-acivated protein kinase kinase  
MLH-1 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) 
MMR Mismatch repair 
MRI Magnetic resonance imaging 
mRNA messenger RNA 
MSH-2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 
MSH-6  mutS homolog 6 (E. coli) 
mTOR Mammalian target of RapaMYCin 
MYC v-MYC myelocytomatosis viral oncogene homolog (avian)  
NEEC Non-endometrioid endometrial cancer 
NER Nucleotide excision repair 
p16 cyclin-dependent kinase inhibitor 2A 
PBS Phosphate buffered saline 
PET Positron emission tomography 
PI3K Phosphatidylinositid 3-kinase 
PIK3CA Phosphatidylinositol-4,5bisphosphate 3-kinase,catalytic subunit α 
PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 
PR  Progesterone receptor 
PTB Phosphotyrosine binding domain 
PTEN Phosphatase and tensin homolog 
qPCR qualitative polymerase chain reaction 
RTK Receptor thyrosine kinase 
RAF v-raf murine sarcoma viral oncogene 
SH2 Src homology domain 
SERM Selective estrogen-receptor modulator 
 
SAM Significance analysis of microarray 
SI  Staining index 
SNP Single nucleotide polymorphism 
TMA Tissue microarray 
TP53 Tumour protein 53 
TSC2 Tuberous sclerosis 2 
 
ABSTRACT 
Background: 
Incidence of endometrial cancer is increasing in industrialised countries. 
Despite early diagnosis and generally good prognosis, around one fourth of 
cases follow an aggressive path with few effective treatment alternatives in a 
systemic disease setting. Key clinical challenges today are to (1) improve the 
identification of these patients with high risk for developing systemic disease to 
individualize surgery and conventional adjuvant treatment; (2) identify targets 
for new treatment strategies in the systemic setting. 
Main objectives:  
The main objective was to explore the potential of mutations and gene copy 
number alteration as biomarkers in endometrial carcinomas and to relate these 
genetic alterations to changes in transcriptional signatures and link to clinical 
phenotype. The goal was to improve the understanding of molecular changes 
identified by a distinct biomarker to promote clinical implementation of 
prognostic biomarkers and further exploration of potential predictive 
biomarkers in clinical trials.  
 
Materials and methods: 
To explore the role of KRAS (paper I) the most frequently genes included in 
8q24 amplifications (paper III) in endometrial cancer, we analysed the relation 
between copy number variations and gene expression using FISH, SNP-arrays, 
q-PCR and microarrays. We also performed a high-throughput mutation 
profiling using mass-spectrometric genotyping of 28 known oncogenes (paper 
II). In total primary tumour samples from 464 patients and 61 metastatic 
lesions were included in the various analysis.  
Results:  
Amplification and gain of KRAS present in 3% and 18% of metastatic lesions 
was significantly related to poor prognosis (paper I). ATAD2 expression was 
most associated with the 8q24 amplification, and related to poor prognosis in 
MYC dependent endometrial cancers (paper III).  FGFR2, KRAS and PIK3CA 
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were the most frequently mutated oncogenes in primary tumours, and 
metastatic lesions.  
 
Conclusions:  
KRAS amplifications increasing from primary to metastatic lesions are relevant 
for endometrial cancer progression (paper I).  High ATAD2 expression is 
indicative of poor prognosis and is suggested treated by HDAC inhibitors 
(paper III). FGFR2, KRAS and PIK3CA are frequent in endometrial cancer, 
with a potential for development of novel therapeutic strategies (paper III). 
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1. Introduction 
 
Endometrial cancer evolves from the endometrium, which is the cell layer 
lining the uterine cavity. Histological, endometrial cancers are often referred to 
as either endometrioid or non-endometrioid carcinomas. The endometrioid 
cancers resemble the endometrial epitelium with gland-like structures, while 
non-endometrioid cancers are more aggressive and include the serous and clear 
cell types. Although most endometrial cancers are detected at early stages, 
untreated or aggressive disease results in metastatic spread. Metastases are 
primarily spread to the vaginal vault, pelvic and para-aortic lymphnodes, 
adenexa and pelvic viscera. Distant spread is dominated by lung metastasis and 
less frequent (<5%)1.  
 
1.1 Endometrium 
 
The uterus is composed of three tissue layers, a thin outer layer of connective 
tissue, a thick layer of smooth muscle (myometrium) and an inner layer of 
epithelial cells, the endometrium. The endometrium prevents the myometrial 
walls to adhere to each other, thereby maintaining the structural integrity of the 
uterine cavity2.  
 
1.2 Epidemiology 
 
Endometrial cancer is the most common gynaecologic malignancy in 
industrialised countries. Nearly 200 000 women is diagnosed with endometrial 
cancer each year, it is the seventh most common malignancy in women 
worldwide, and for those affected the disease has major impact on morbidity 
and mortality for this group3.   
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In Norway the prevalence of endometrial cancer is 17/100 000 women each 
year. Of all cancers diagnosed in women in Norway from 2006 – 2010, 6% 
were diagnosed with endometrial cancer, and the cumulative risk of developing 
endometrial cancer is 2.1%4. Endometrial cancer is most common in elderly 
women, and more than 90% of cases are diagnosed after the age of 50, peaking 
at 70-74 years of age (110/100 000).  The overall incidence of endometrial 
cancer in Norway is increasing (figure 1), it is predicted to increase even more 
the next decades5,6. The overall increase is to a certain extent explained by a 
higher life expectancy, but also the increasing rate of obesity7.  
In general endometrial cancer has a good prognosis, in Norway 2010 the 
overall five year survival rate was 84.4 %4.   
 
 
 
Figure 1. Age adjusted incidence rate of endometrial cancer in Norway per 
100 000 per 5-year period of diagnosis 
 
Adapted from Cancer Statistics Norway 2010.4 
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1.3 Etiology and risk factors 
 
Most endometrial cancers are sporadic, however several risk factors has been 
implicated for the disease.  The most significant risk factor in sporadic cases is 
the exposure to unopposed oestrogen8.  In women who use unopposed 
oestrogen the risk of developing endometrial cancer is two to ten times 
higher9,10.  Endometrial cancer risk has also been linked to the use of selective 
oestrogen-receptor modulators (SERMs), especially Tamoxifen frequently used 
in breast cancer treatment11. However, this observation was predominantly in 
postmenopausal women, backing the theory of unopposed oestrogen12.  Obesity 
is also an established risk factor in endometrial cancer13. Adipose tissue secrete 
the oestrogen oestrone, and is relevant to endometrial cancer development due 
to the conversion of oestrone to oestradiol, that have a more potent oncogenic 
effect14,15.  Another effect of obesity is insulin resistance in relation to type II 
diabetes, which again increases the bioavailability of insulin growth factor-I 
(IGF-I)16.  IGF-I has been implicated in cancer development due to its 
mitogenic and anti-apoptotic effects, but also its effect on the phosphorylation 
of oestrogen-receptor alpha (ER-α). Phosphorylation of ER-α increases its 
activity, which again up-regulates the expression of IGF-I, causing a positive 
feedback loop17.   
 
An inverse association between parity and endometrial risk has been shown in 
numerous epidemiological studies18,19.  Reasons for the increased risk in 
nulliparous women might be due to pregnancy related factors such as reduced 
periods of unopposed oestrogen during the pregnancy or shedding of 
premalignant cells at delivery19. Late age at last birth has also been linked to 
reduced risk of endometrial cancer20. 
 
Although most endometrial cancers are sporadic, about 5 - 10% of cancers 
have hereditary basis12. A large part of these cases are associated with 
hereditary non-polyposis colorectal cancer (HPNCC) also known as the Lynch 
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syndrome, which is a dominantly inherited syndrome with germline mutations 
in mismatch repair (MMR) genes, that may lead to microsatellite instability 
(MSI)21.  Women with Lynch syndrome have a tenfold higher risk of 
developing endometrial cancer compared to the general population. They also 
develop endometrial cancer at an earlier age, around two decades earlier than 
median age for onset of the disease in sporadic cases 22,23. 
 
 
 
1.4 Clinical aspects and diagnosis   
  
Abnormal vaginal bleeding is the most common symptom in endometrial 
cancer patients, and occurs in more than 90% of patients24. During menopause 
irregular bleeding is common, due to hormonal fluctuations25.  However, 
postmenopausal bleeding is a disconcerting symptom urging the majority of 
women to seek medical care. Of this patient group approximately 10% is 
diagnosed with endometrial cancer26.  
 
1.4.1 Diagnosis 
 
The preliminary diagnose is based on sample collection of endometrial tissues 
by the dilatation and curettage (D&C) procedure or an office biopsy prior to 
primary surgical treatment. The histopathological diagnosis with assessment of 
depth of myometrial invasion and extra uterine disease will be the foundation 
in the planning of further therapy. Evaluation of histological subtype and grade 
is critical as a part of the preoperative workup to classify the patients into low-, 
intermediate- and high risk groups (see table 1)27.   
 
 
 
 
 F
Table 1.  Parameters for risk stratification in endometrial cancer. 
 
Clinicopathologic- 
parameters 
Low Risk Intermediate Risk High Risk 
FIGO stage I I II,III and IV 
Type Endometriod 
adenocarcinoma 
 
Endometrioid 
adenocarcinoma 
 
None-Endometriod  
carcinoma 
Myometrial 
invasion  
<50% of  ≥ 50% of   
Adapted from Rose (1996)28. 
 
A full histological evaluation of the hysterectomy specimen decides the final 
surgical FIGO staging and subsequent treatment. The correlation between 
preoperative specimens (endometrial biopsy) and postoperative hysterectomy 
specimens varies. Werner et al29, reports that 16% (207 out of 1288 cases) had 
discordant histological risk classification, comparing preoperative and 
postoperative biopsies in endometrial cancer. This study also showed that the 
patient group with discordant risk classification had an intermediate overall 
survival compared to the groups where either concordant low or high-risk 
classification.  
  
Vaginal ultrasound, gross inspection of the uterus during surgery and frozen 
section evaluation may be helpful tools to evaluate depth of myometrial 
invasion pre- and peri-operatively27.  MRI is widely used to detect cervical 
involvement and presence of extra uterine disease prior to primary surgery.  
Other preoperative methods used for this are computer topography (CT), Chest 
X-ray and positron emission topography (PET). Chest X-ray is used to identify 
distant metastasis together with PET. MRI and ultrasound have been shown to 
be superior to PET in terms of assessment of myometrial invasion, however in 
terms of detection of metastasis PET is superior30. Still, it is a challenge to 
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detect lymph node metastases by imaging methods, and lymphadenectomy is 
thus widely used for intermediate and high risk patients8.     
 
 
1.4.2 Staging of endometrial cancer 
 
Endometrial carcinoma has since 1988 been surgically staged by the 
International Federation of Gynaecology and Obstetrics (FIGO) staging 
system, last revised in 200931. FIGO stage is the strongest prognostic factor in 
endometrial cancer (Table 2). Together with histopathological sub-typing and 
grading, FIGO stage sets the basis for further treatment and the final diagnosis 
after surgery (see figure 2).  
 
Table 2. International Federation of Gynecology and Obstetrics staging 
system for endometrial cancer, 2009 
 
Stage Description 
I Tumour confined to the corpus uteri 
IA No or less than half myometrial invasion 
IB Invasion equal to or more than half of the myometrium 
II Tumour invades cervical stroma, but does not extend beyond the uterus* 
III Local or regional spread of tumour, or both 
IIIA Tumour invades the serosa of the corpus uteri or adnexae, or both† 
IIIB Vaginal or parametrial involvement or both† 
IIIC Metastases to pelvic or para-aortic lymph nodes or both† 
IIIC1 Positive pelvic nodes 
IIIC2 Positive para-aortic lymph nodes with or without positive pelvic lymph nodes 
IV Tumour invades bladder or bowel mucosa or distant metastases or all three 
IVA Tumour invasion of bladder or bowel mucosa or both 
IVB 
Distant metastases including intra-abdominal metastases or inguinal lymph nodes or 
both 
At all stages tumour grade can be 1, 2, or 3. 
 
* 
Endocervical glandular involvement should be considered only as stage I and no longer as stage II 
† Positive cytology has to be reported separately without changing the stage. 
Pecorelli et al31. 
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Figure 2. Differentiation, grade and tumour type versus prognosis in 
endometrial cancer 
 
1.5 Treatment 
 
1.5.1 Primary treatment 
 
The primary treatment for endometrial cancer is surgery. In low risk FIGO 
stage I disease, simple hysterectomy with bilateral salpingoophorectomy is the 
standard treatment. For high-risk cases lymph node staging is also 
recommended, and omentectomy for non-endometrioid cases27. For the 
intermediate risk group lymphadenectomy is also often performed, and may be 
valuable to guide further adjuvant therapy.  For locally advanced and 
metastatic cancers the therapy is individualised, with more extensive surgery, 
including para-aortic lymph node removal in some cases. Although several 
studies have shown a prognostic value of pelvic- and para aortic lymph node 
GradeDifferentiation Histologic type
1 (low)
2 (moderate)
3 (high)
High
    Moderate
Low
Non-endometroid
Endometrioid
Endometrioid
Numerical system of 
differentiation based 
on morphology of 
tumor sections.
Histologic types 
included in
non-endometrioid
Clear cell
Serous papillary
Undifferentiated
Carcinosarcoma
Prognosis
Good
Poor
Endometrioid
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sampling, the impact on survival is uncertain, so the importance of pelvic and 
para aortic lymph node removal still remains controversial8. 
 
1.5.2 Adjuvant treatment 
 
Adjuvant treatment is given to presumed cured patients that are classified as 
high-risk patients for developing recurrent disease locally or at distant sites.  
The most used adjuvant therapy in endometrial cancer has been pelvic radiation 
therapy but adjuvant chemotherapy has been increasingly used over the last 
years8. Low risk and early stage cancers are often treated only with surgery, 
and in most cases without adjuvant treatment. These patients hold in general a 
good prognosis. In the group of patients that have been defined as intermediate 
risk, randomised studies has shown no effect of adjuvant radiotherapy8. In 
patients with advanced disease treatment management is more complex.  The 
treatment is individualized and may be a combination of surgery, radiotherapy, 
chemotherapy and anti hormonal treatment. 
 
1.5.3 Biomarkers 
 
A biomarker is a characteristic that can be objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention32.  In medicine 
biomarkers are often separated in two groups, prognostic biomarkers and 
predictive biomarkers. Prognostic biomarkers indicate a patients overall disease 
outcome regardless of treatment, while predictive biomarkers will provide 
information on the effect of a therapeutic intervention33.   
 
Prognostic markers.  
 
In endometrial cancer, surgical FIGO stage remains the strongest prognostic 
factor.  Still, 20% of patients presumed to have good prognosis based on FIGO 
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stage, experience recurrent disease 33. Consequently, in order to improve 
stratification of endometrial cancer patients for adjuvant therapy and advanced 
surgery, much effort is put into development of new diagnostic tools to 
individualize treatment.   
Several prognostic biomarkers have been identified in endometrial carcinoma. 
The most studied is the steroid hormone receptors, oestrogen and progesterone 
receptor (ER, PR). Expression of ER and PR is associated with favourable 
prognosis in endometrial cancer34,35.  Another prognostic factor is DNA ploidy. 
Normal cells are diploid, and contain two sets of chromosomes, one inherited 
form each parent. Aneuploid cells on the other hand have several sets of 
chromosomes, and is related with poor prognosis in endometrial cancer36.  Also 
TP53 over-expression has consistently been associated with non-endometrioid 
histology and poor outcome37. 
 
Predictive biomarkers 
It is a goal that improved knowledge about the molecular characteristics of a 
patient’s disease will become more useful to tailor treatment to the individual’s 
requirement and to predict response. Molecular tests that provide information 
regarding gene mutations, protein expression or metabolites, may be used to 
determine the efficacy of a certain treatment. In endometrial cancer hormone 
receptor status has been shown to reflect efficacy of anti-hormonal therapy, but 
beyond that, no predictive markers are available or in use in standard clinical 
care in endometrial cancer treatment38. 
 
1.5.4 Targeted therapies - Clinical trials 
 
Currently, treatment of metastatic and recurrent endometrial carcinoma is 
based on conventional chemotherapy regimens and antihormonal treatment, 
with no new and more targeted therapies available for clinical use. Modest 
response rates have been seen in clinical phase 1 and 2 trials testing EGFR, 
HER2, and VEGFR inhibitors39. It should be kept in mind that some of these 
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inhibitors may have an unexplored potential as they have only been studied as 
monotherapy in heavily pretreated patients. There has also been a lack of 
biomarker restriction in the studies. Recent comprehensive molecular 
characterisations of primary tumours have identified drugs targeting the 
PI3K/PTEN/AKT/mTOR pathway and FGFR2 (fibroblast growth factor 
receptor 2) as promising targets for further studies, also reflected in ongoing 
clinical trials of endometrial carcinomas27,40.  
      
1.6 Molecular aspects of endometrial cancer 
 
1.6.1 Tumour biology in brief 
 
Cancer is a broad group of diseases, all involving unregulated cell growth.  
Solid tumours like endometrial cancer can also invade the surrounding tissues 
and metastasise to distant locations. Cancer development is a stepwise process 
where the cancer cells acquire several properties. These steps are often referred 
to as hallmarks of cancer, first proposed by Douglas Hanahan and Robert A. 
Weinberg41. The first step and most crucial property of cancer cells is sustained 
growth. Normal tissues cautiously control the production and release of growth 
promoting signals. These signals order the cell to enter the growth and dividing 
cycle of the cell, and thus protect the homeostasis with respect to cell number, 
tissue architecture and function. However in cancer this level of control is 
disrupted, leaving the cancer cells as masters of their own growth and 
proliferation42. Cancer cells can acquire these properties in several ways: The 
cancer cells can produce their own growth factors, which in turn can activate 
the respective growth factor receptor. Alternatively the cancer cells may send 
signals to the surrounding tissue, that in response will supply the cancer with 
various growth factors43.  
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The cancer cells may also be independent of growth factors due to activating 
mutations in the respective growth factor receptors, and activating mutations in 
downstream activators of the growth factor receptor44.  
However, in normal cells unregulated growth will be terminated due to 
powerful programs that negatively regulate cell proliferation45. Many of these 
programs depend on tumour suppressor genes.  When these tumour suppressor 
genes are activated this leads to regulated cell death or cell cycle arrest46.  In 
cancer cells tumour suppressor genes are typically mutated in a way that leads 
to non-functional proteins, or the gene may be deleted leading to no protein 
product at all.  This able the cancer cells to divide uncontrolled without 
presence of the normal mechanisms for inhibition47.   
 
A limiting factor for uncontrollable growth is oxygen. When a body of cells 
reach the size of 2-3 mm, hypoxia occurs, and waste products like CO2 and 
NH3 will accumulate48. The tumour is then dependent on inducing angiogenesis 
both for waste removal and oxygen supply. This enables the tumour to grow 
further in size49. 
 
The next step and hallmark in tumour development is metastasis, a multistep 
process where cells from the primary tumours: (1) Locally invade through the 
extra cellular matrix (ECM) and surrounding stromal tissues, (2) intravasate 
into the lumina of blood vessels or lymph vessels, (3) survive the severe 
transport through blood vessels or the rigours environment of the lymphatic 
system, (4) settle down at distant organ sites, (5) extravasate into the 
pharenchyma of distant tissues, (6) survive in the foreign tissue in order to 
form micrometastases, (7) re-establish their proliferative programs in the new 
tissue, forming macroscopic, clinically neoplastic growths50.  
 
1.6.2 Genetic mutations in cancer 
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Many of the processes described in section 1.6.1 are considered related to 
genetic alterations.  Genetic changes can occur in several forms including, 
amplifications, deletions, translocations and point mutations of the respective 
genetic sequences.  The human genome is dynamic and it is estimated that a 
cell undergoes > 20,000 DNA damaging events and >10,000 replication errors 
per cell per day51. Normally cells repair DNA damages through base excision 
repair (BER) and nucleotide excision repair (NER) and replication errors 
through mismatch repair (MMR)52.Mutations occur when DNA polymerases 
encounter damaged bases and inserting a non-complementary nucleotide 
opposite the lesion that gives rise to a permanent and heritable change in the 
DNA sequence53.  Unrepaired DNA damages and crosslink’s that block DNA 
replication can result in chromosome rearrangements.  
 
“The essence of life is statistical improbability on a colossal scale” 
Richard Dawkins 
 
The number of genes that regulate DNA replication processes in human cells is 
not known. Studies of different species such as yeast suggest that >100 genes 
are involved in these processes, including DNA polymerases. Mutations in 
these genes including BER, NER and MMR genes speed up the mutation rate 
of cancer. By the time a solid tumour reaches the size of 1cm3 or 108 – 109 
cells, each cell will contain tens of thousands of clonal, subclonal and random 
mutations (Figure 3.)51.  Most of these mutations will not affect the cellular 
phenotype and are often referred to as “passenger mutations”, however a 
certain proportion will affect the cellular phenotype, hence called “driver 
mutations”54. 
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Figure 3.  Illustration of model for general mutagenesis in cancer 
Hexagons (red) represent mutations in genes that result in enhanced mutagenesis, spheres (yellow) 
indicate driver mutations that are selected on the basis of changes in the tumour microenvironment and 
triangles (green) represent passenger mutations (adapted from Loeb, 201152). 
 
1.6.3 Point mutations (single base substitutions) 
 
Point mutations are the most common mutations in cancer. They commonly 
arise from DNA polymerase errors that are avoided by MMR55. Normally these 
mutations are random events that do not alter protein function56.  However in 
some cases a single base substitution leads to altered protein function.  A 
typical example of such event is the oncogenic transformation of v-Ki-ras2 
Kirsten rat sarcoma viral oncogenes homolog (KRAS).  A single base change, 
guanine to thymine in codon 12 of the KRAS gene leads to an amino acid 
change from glycine to valine, which renders the conformation of the translated 
protein from an inactive state to a constitutively active state57.   However point 
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mutations can also lead to inactivation of proteins, by changing the 
conformation of the translated protein or by affecting the transcription of the 
gene itself58.  
 
1.6.4 Copy-number alterations 
 
Genomic copy-number alterations are a consequence of genomic re-
arrangement. Mechanisms involved in the process of copy-number changes are 
mutations leading to DNA breakage, or mutations leading to impaired 
replication fork strand priming59. Various types and sizes of copy-number 
alterations can be detected such as large gains or losses (>1Mb) and high-level 
amplifications (>8 gene copies/diploid genome), or large and focal losses60. 
Across the genome the most prevalent copy-number alterations are either very 
short (focal) or almost exactly the length of a chromosome arm or a whole 
chromosome. Focal copy-number changes occur at a frequency inversely 
related to their length with a median length of 1.8Mb (range 0.5kilobases (kb)-
85Mb)61.   
DNA copy-number amplification is a focused genomic alteration that result in 
an increased quantity of genes within the amplified region62. A gene 
amplification refers to >4 copies of a DNA segment that is less than 20Mb in 
length. However in some cancer types like neuroblastoma and glioma, v-MYC 
myelocytomatosis viral oncogene homolog (MYC) and epidermal growth factor 
receptor (EGFR) are highly amplified (>100 copies)63,64.  Gene amplifications 
affects intra chromosomal DNA and depends on DNA double strand breaks 
occurring at the end of the amplified region. Low-level amplifications (<4) 
referred to as gains normally results from ploidy changes or unequal 
translocations63,64.  
Deletions involve the loss of DNA sequences65. The effect of a given deletion 
on phenotype depends on the size and the location of the deletion. An example 
is deletions that span the centromere will result in an acentric chromosome66. 
The acentric chromosome will most likely be lost during mitosis resulting in a 
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daughter cell lacking essential genes66. However, focal deletions could also 
occur, where one copy of a gene is lacking on one allele. This specific gene 
deletion will cause a mutant phenotype called haploinsufficiency67. In cancer 
this has been shown for the commonly mutated tumour suppressor gene in 
endometrial cancer, phosphatase and tensin homolog (PTEN)68.  
 
1.6.5 Genetic alterations in endometrial cancer. 
 
 Traditionally endometrial cancer has been divided into two groups, type I and 
type II, on the basis of clinicopathologic studies69.  Type I endometrial cancer 
are represented by low-grade endometrioid carcinomas. They represent 
approximately 80% of endometrial cancer tumours70.  Type I tumours are often 
oestrogen related, they occur in both premenopausal and postmenopausal 
women, they arise from of endometrial hyperplasia and are in general 
associated with good prognosis71. Type II endometrial cancer is dominated, 
although with exceptions by non-endometrioid tumours, they are usually not 
oestrogen related, occur in postmenopausal women, and are associated with 
poor prognosis72. In recent years an increasing number of publications 
exploring genetic alterations involved in endometrial cancer, have identified 
different molecular characteristics for these tumour types.  Type I cancers often 
show mutations in PTEN, KRAS, β-catenin, as well as DNA mismatch repair 
genes such as MLH-1, MSH-2 and MSH-6, together with cyclin D1 over-
expression40,73-77. Type II endometrial cancer is characterized by TP53 
mutations, HER2 amplification, and inactivation of p1678-80. In addition, both 
amplifications and deletions of key cancer genes have been reported in 
endometrial cancer81. Several signalling pathways are linked to these genes, of 
which the most relevant to endometrial cancer are described in the following. 
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1.6.6 Receptor tyrosine kinase signalling in endometrial cancer 
 
Alterations in receptor tyrosine kinase (RTK) signalling are very often 
implicated in tumorigenesis82. Mutations may occur both in the RTK´s 
themselves and in their downstream effectors83,84. RTK signalling is involved 
in several processes including cell proliferation, cell differentiation, 
angiogenesis and cell survival85.  
 
Figure 4. Schematic presentation of the receptor tyrosine kinase signalling 
pathway 
RTKs mediate signals through both the PI3K and KRAS pathways. Activating mutations in PIK3CA 
and KRAS has been implicated in endometrial tumorigenesis. 
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Humans have 58 different RTK´s divided into 20 sub families86. Most RTK´s 
are single unit receptors that dimerise upon ligand binding87.  Each monomer 
has a transmembrane-spanning domain, an extracellular C-terminal and an 
intracellular N-terminal88. The intra cellular kinase domain transfers phosphate 
from high-energy molecules such as adenosine tri-phosphate (ATP) to specific 
substrate molecules.  Kinase enzymes that specifically phosphorylate tyrosine 
residues are called tyrosine kinases89.   
 
Phosphorylation of tyrosine residues within the receptor generates binding sites 
for Src-homology (SH2) domain and phosphotyrosine binding (PTB) domain-
containing proteins90. These evolutionary conserved domains are found in a 
large range of proteins and makes RTK signalling very diverse. The typical 
SH2 domain containing protein involved in RTK signalling is growth factor 
receptor-bound protein 2 (GRB2) and a typical PTB containing protein is 
insulin receptor substrate 1 (IRS1)91,92. In endometrial cancer alterations in 
RTK´s such as ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 2, (HER2)), EGFR (epidermal growth factor receptor) and FGFR2 
(fibroblast growth factor receptor) have been implicated in disease 
progression79,93. RTKs can signal through several effector proteins89. In 
endometrial cancer the most studied downstream effectors are PI3K, PTEN and 
KRAS.  
 
KRAS is a small GTPase and a member of the RAS superfamily94. It is 
activated by guanine nucleotide exchange factors (GEFs), where son of 
sevenless (SOS) is the most prominent, which remove guanine diphosphate 
(GDP) from the inactive protein, and the more abundant guanine triphosphate 
(GTP) will then bind and activate the protein95. KRAS is inactivated by GTPase 
activating proteins (GAPs), which hydrolyses GTP to GDP96. In humans KRAS 
is involved in cell proliferation, development and cell survival97. KRAS is the 
most frequently mutated oncogenein cancer, and one of the first oncogenes to 
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be discovered98. The mutated form of KRAS is insensitive to GAPs and is 
therefore constitutively active99. Several mutations have been detected in the 
KRAS gene, however three hotspot areas are the most common, codon 12, and 
13 of exon 2 and codon 61 of exon 199.  In endometrial cancer KRAS has been 
reported mutated in 10 to 20%100,101.  The standard route of KRAS signal 
transduction goes through v-raf murine sarcoma viral oncogene (RAF), 
mitogen-acivated protein kinase kinase (MEK) and extra cellular regulated 
kinase1/2 (ERK1/2), which again activate the transcription factor Elk1102,103. 
However, ERK1/2 can also activate the mammalian target of rapamycin 
(mTOR) through the inhibition of tuberous sclerosis 2 (TSC2)104. ERK1/2 is 
also known to stabilize and enhance the activity the activity of MYC105.  
 
The MYC gene (v-MYC myelocytomatosis viral oncogene homolog), a 
transcription factor reported to be relevant in several cancer types, including 
leukemia, breast cancer and prostate cancer106-108. The MYC proto-oncoprotein 
can regulate 10-15% of all genes through its helix-loop-helix leucine zipper 
domain, and affects proliferation, growth and differentiation109,110.  In 
endometrial cancer MYC amplification has been linked to poor prognosis.  
 
Another protein downstream of RTKs, which is implemented in endometrial 
carcinogenesis, is PI3K. PI3K is encoded by the PIK3CA gene, which codes for 
the 110α catalytic subunit of phosphatidylinositol-4, 5-biphosphate 3-kinase 
(PI3K).  The protein also consists of the phosphoinosiyide-3-kinase, regulatory 
subunit  (PIK3R1, p85). The catalytic subunit of PI3K phosphorylates PIP2 
(phosphatidylinositol (4,5)-diphosphate) to PIP3 (phosphatidylinositol (3,4,5)-
triphosphate, which again recruits AKT (v-AKT murine thymoma viral 
oncogene homolog) to the cell membrane where AKT phosphorylated by 
PDK1111,112. AKT is involved in cell survival and cell proliferation113.  PIK3CA 
amplification and increased PI3K signaling have been linked to poor prognosis 
in endometrial cancer38,81.  The PI3K/AKT signalling pathway is regulated by 
phosphatase and tensin homolog (PTEN)114.  
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PTEN acts as a tumour suppressor through its phosphatase protein product, by 
dephosphorylation of PIP3 to PIP2, thereby inhibiting the phosphorylation of 
AKT114. PTEN also act as a tumour suppressor by activating the apoptotic 
machinery115. In cancer PTEN is often mutated or deleted. In endometrial 
cancer PTEN is found mutated in 38%116.  
 
Another prominent tumour suppressor involved in endometrial cancer is TP53. 
The TP53 gene encodes tumour protein 53 (TP53), which is a tumour 
suppressor. TP53 responds to various cellular stress stimuli and regulates the 
transcription of genes involved in apoptosis, cell cycle arrest, changes in 
metabolism and DNA repair, hence the name “Guardian of the Genome”117. 
The TP53 gene is frequently mutated in human cancers causing loss of tumour 
suppressor function118. In endometrial cancer TP53 is mutated in approximately 
20% of cancers, and is related to non-endometrioid tumours and poor 
survival116,119.   
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2. Aims of the study 
 
2.1 Background  
 
Endometrial cancer is the most common pelvic gynaecologic malignancy. 
Although endometrial cancer patients in general have good prognosis, 15 – 
20% have recurrent disease. Surgical removal of the tumour is the main 
component of therapy; in cases with severe disease adjuvant therapy is given 
by chemotherapy, hormonal therapy or radiation. However in metastatic 
disease conventional sytemic therapy has limited effect, and there are currently 
no targeted therapies approved for standard clinical care for these patients. 
Hence, the identification of new prognostic markers and drugable targets for 
this patient group is critical to improve therapy.  
 
2.2 General aims 
 
The general aim for was to study to what extent biomarkers change from 
primary tumours to metastatic lesions, and to what extent they may represent 
new potential relevant targets for therapy in primary lesions with high risk of 
recurrence and metastatic lesions.  
A secondary aim was to identify transcriptional alterations in endometrial 
cancer related to mutations and gene amplification.  
Third, we wanted to screen a number of known oncogenes for mutations 
known from other cancer types in primary and metastatic endometrial 
carcinoma lesions.    
 
2.3 Specific aims 
 
1. To explore the relevance of KRAS mutations and KRAS gene 
amplification in primary and metastatic lesions of endometrial cancer. 
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Investigate the findings in relation to clinicopathologic parameters and 
patient prognosis. Indentify new biomarkers by comparing tumours with 
KRAS amplification and KRAS mutation to gene expression data (Paper 
1). 
 
2. To explore the distribution of known oncogenic point mutations by 
using mass spectrometric genotyping in endometrial cancer to 
characterize frequency of these amongst which more targeted therapies 
may exist or be in development (Paper II). 
 
3. To investigate the amplification of chromosome 8q24 in endometrial 
cancer in relation MYC and the co-regulator of MYC, ATAD2. To 
investigate the relation between MYC and ATAD2 status en relation to 
endometrial cancer disease progression and transcriptional alterations 
suggesting targets for therapy.  
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3. Summary of results 
 
The work presented in this thesis has provided new insight regarding: 
• KRAS amplification and mutation status in endometrial cancer. 
• Potential targets for new treatment strategies related to alterations in 
oncogenes in endometrial cancer 
• The role of ATAD2 over-expression in MYC dependent endometrial 
cancers. 
 
Paper I 
 
Analysis of KRAS copy number changes by FISH analysis showed a large 
variation in KRAS/CEP12q gene probe ratio from 2:2 to <20:2 in endometrial 
cancer. Presence of KRAS gain or amplification was significantly associated 
with traditional markers for aggressive phenotype including high age, FIGO 
stage, non-endometrioid histology, high grade, and presence of lymph node 
metastasis, aneuploidy and loss of hormone receptors. KRAS gain or 
amplification was also highly significantly associated with poor prognosis. 
When comparing primary and metastatic endometrial carcinoma lesions, we 
found a significant increase in the proportion of samples with KRAS gain or 
amplification  
High KRAS mRNA expression was equally significantly associated with high 
FIGO stage, non-endometrioid histology, high grade, lymph node metastasis, 
aneuploidy, and hormone receptor loss. The KRAS mRNA levels increased 
significantly from primary to metastatic lesions and in amplified compared to 
unamplified samples. In line with this, high KRAS mRNA level was associated 
with poor prognosis in the validation cohort  
In addition we found that 14.7% of primary tumours harboured mutations in 
exon 2 of the KRAS gene. KRAS mutations were significantly more often 
 CD
present in grade 1 and 2 tumours, the endometrioid subtype and among obese 
patients. In accordance with this, KRAS mutations did not influence prognosis. 
 
 
Paper II 
 
Through mass spectrometric genotyping (OncoMap) we found that 40.3% of 
endometrial cancer patients had point mutations in one single gene, while 6.0% 
had mutations in 2 genes for the 26 oncogenes tested for. Among the seven 
genes with detected somatic mutations in primary and metastatic lesions, KRAS 
(17.9%), PIK3CA (14.6%) and FGFR2 (10.4%) were the most frequently 
mutated, while mutations in BRAF (1.5%), EGFR (1.5%), HRAS (1.5%) and 
NRAS (1.5%) were rare. The most common single mutation found was FGFR2 
S252W (9.0%), however the most frequently mutated gene was KRAS (17.4%). 
We also screened of 11 established endometrial cancer cell lines and identified 
KRAS, PIK3CA and FGFR2 to be the most commonly mutated oncogenes.  
To further investigate if the mutation pattern changed during disease 
progression, 15 metastatic lesions from 9 patients from which seven had 
primary tumors available for comparison, were analyzed for mutations. KRAS, 
PIK3CA and FGFR2 were found to be the most frequently mutated genes also 
in metastatic lesions, with no significant increase in mutation frequency.  
 
Paper III 
 
Through SNP and microarray analysis we found that both MYC and genes up 
regulated by MYC were over-expressed in endometrial cancers with 8q24 
amplification relative to endometrial cancers without this gene alteration.  
However, variations in MYC expression itself only explained a small 
proportion of variations in MYC signalling strength.  
Expression of ATAD2 was more strongly associated with amplification of 8q24 
than was expression of any other gene in the peak region of the amplification. 
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Expression of ATAD2 also correlated with MYC signalling strength more 
strongly than did expression of any other gene in the 8q24 peak region. The 
correlation between ATAD2 expression and MYC signalling strength was 
stronger than for MYC itself. Among the 70 endometrial cancers for which we 
had genome-wide SNP array data, 8q24 amplification was associated with 
reduced progression-free survival and increased risk for disease-specific death.  
ATAD2 expression was higher in non-endometrioid, high-grade and ER 
negative tumours. Metastases also exhibit more 8q24 amplification, ATAD2 
expression, and MYC signalling strength than primary tumours.  
Expression of ATAD2 correlated with 8q24 amplification breast cancers, 
glioblastomas, and ovarian cancers. Knockdown of either ATAD2 or MYC 
resulted in highly correlated decreases in viability across the seven cell 
endometrial cancer lines. The same cell lines were also the most sensitive to 
the histone deacetylase (HDAC) inhibitor Trichostatin-A. 
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4. General discussion 
 
4.1 Methodological considerations 
 
4.1.1 Patient series and sample selection 
 
Primary and metastatic tumour lesions from endometrial carcinoma patients 
were collected prospectively from 2001 together with clinical data and studied 
in this project; 1) Fresh frozen tumour tissue (FFT) was applied for microarray, 
SNP array and mutation detection studies (n= 286) in Papers I, II, and III. 2) 
FFPE (formalin fixed paraffin wax embedded) tissue partially overlapping with 
the fresh frozen specimens was used for FISH and immunohistochemical 
staining (n=415 primary tumours and 61 metastatic lesions) in papers III and I). 
In total, tumour samples from 463 patients were used in the studies. 
 
An overview of samples studied and methods applied is given in table 3. 
 
Table 3 Methods, tissue types and number of samples included in the 
studies.  
 
Method FFT FFPE 
Primary 
tumours (n) 
Metastatic 
lesions (n) 
FISH  x 415 61 
SNP-array x  74 0 
Microarray x  122 22 
Sanger sequencing x  264 22 
Oncomap x  67 14 
qPCR-array x  162 0 
 
The smaller series with fresh frozen tissue were used for methods requiring 
samples with high quality DNA and RNA. For these studies hematoxylin 
stained frozen full-sections were analysed for tumour purity. The samples used 
contained a minimum of 50% tumour cells, but the majority of samples 
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contained 80% tumour cells or more. In genome wide studies such as SNP-
arrays and microarrays the platform providers often recommend the use of 
samples with high tumour purity, as stromal contamination may result in 
reduced detection of alterations in the malignant epithelial component120. This 
may however lead to a systematic bias in the inclusion of the patients. A study 
from our group has shown that enriching for samples with high tumour content 
leads to selection of more aggressive cancers with higher grade, deep invasion 
and poor survival121. This might also be due to a larger tumour size for the 
more aggressive phenotype making it easier to retrieve sufficient material with 
lower stromal cell contamination. In line with this, a recent study has shown 
that tumour volume in endometrial cancer patients is related to poor 
prognosis122. On the other hand, selection of more aggressive tumours may be 
an advantage when searching for therapeutic targets in patients with systemic 
disease. Still, potential biomarkers detected will need to be validated in a more 
population based setting for distribution and relevance in a routine clinical 
setting. Thus, the potential selection bias is important to keep in mind for 
interpretation of results and further analyses.  
For the construction of TMAs hematoxilin stained FFPE tumour sections were 
investigated to select area of representative tumour tissue. In cases with tumour 
heterogeneity, the densest and least differentiated area was selected. This was 
used as a guide for punching out cylinders for the TMAs both for primary 
tumours and metastatic lesions. The TMA method has been validated in several 
studies by comparing the TMA cores to the corresponding whole tissue 
sections by methods such as FISH and IHC123-126. A study performed on 97 
breast cancer specimens, one TMA and corresponding full sections showed a 
concordance of 97% for ER staining, 98% for PR and 90% for HER2 
amplifications (kappa value > 0.90)124. Another study on 114 breast cancer 
samples comparing the concordance between TMAs and whole tissue sections 
in regard to HER2 amplification shows 86% concordance125. These studies also 
support that TMAs are representative to the tissue they are collected from, and 
may be viable to use in clinical studies. 
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4.1.2 Clinical data 
 
For all patients, clinical data for parity, menopausal status, height and body 
weight, age at primary diagnosis, date of diagnosis, type of primary and 
adjuvant treatment, FIGO stage (according to 2009 criteria) was collected. 
Histopathologic diagnoses were retrieved from routine histopathology reports 
generated in a tumour board setting with clinicians and designated pathologists 
for gynaecologic pathology. For the prospective investigation series of 76 cases 
explored by SNP array and mRNA microarray, histopathological diagnoses 
were revised by an experienced pathologist. The clinical data were retrieved 
from the patient’s hospital records.  
 
4.1.3 Fluorescence in situ hybridization (FISH) 
 
For the detection of KRAS and MYC copy number alterations (For KRAS and 
MYC copy number determination) (Paper I and Paper III) Fluorescent In Situ 
Hybridization (FISH) was performed. This method is a clinically well 
established molecular pathological routine standard method in clinic, used for 
e.g. detection of EGFR and HER2 copy number (CN) status (gene copy 
number increase / gene amplification) predicting response to concerning 
therapeutic growth factor signal pathway inhibition 127-131. Compared to non-
morphological methods, one main advantage of FISH is the “In Situ” ability to 
take morphological tissue properties into account, facilitating to consider 
tumour heterogeneity and to distinguish between tumour and non-tumour cells. 
The direct visualization of gene copies in single nuclei allows a differentiated 
copy number determination and conclusions about the type of copy number 
abberations132. In Paper I we show that KRAS copy number is elevated in 3% 
of endometrial cancers with an increased rate 15% of such copy number 
aberrations in metastatic lesions. In PAPER III we show that 5% of 
endometrial cancer patients harbour MYC amplifications and the frequency 
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increases in metastatic lesions. For both KRAS and MYC presence of 
amplification is related to poor survival, high grade and high FIGO stage.  
 
A previous study from our group assessing genome wide copy number 
alterations by SNP arrays (n=84) support our present findings linking CN 
elevations of KRAS and MYC to features linked to poor prognosis81. However 
when comparing the two methods, there is a discrepancy in the rate of CN 
elevations for MYC and KRAS detected by FISH compared to SNP array. The 
proportions of such cases for MYC and KRAS by SNP array analysis were 27% 
and 13.5% respectively. There may be several reasons for this discrepancy. The 
most likely reason is that the majority of amplifications detected by SNP array 
were low-level amplifications with regarding MYC and KRAS. The results from 
our FISH studies shows that the majority of amplified cases are low-level 
(CEP/gene probe ratio 2:4). One of the challenges with low level 
amplifications and FISH is that tissue sections are two-dimensional while cells 
are three-dimensional. When tissue sections of 5 μm are prepared the nuclei of 
cells are cut in two in some cases. This causes loss of signal, and may affect the 
results, especially for cases with low-level amplifications. These issues will 
also affect the applicability for the method to assess low-level amplifications as 
prognostic or predictive biomarkers in the routine clinic. A possible way to 
overcome this is by extracting the nuclei from the tissue before FISH analysis. 
In addition to reducing the signal loss due to sectioning of tissue blocks, this 
would also decrease background noise133. Another reason for the lower rate of 
amplifications in the patient analysed by FISH could be intra tumour 
heterogeneity. Several studies have reported on this130,134,135. The tumour part 
you choose to analyse may affect your results, i.e myometrial infiltrating front 
versus the front facing the uterine cavity. We used a standard applied method 
for our FISH studies using TMAs. TMAs allow for rapid analysis of a large 
number of tissue samples at a time, and the technique facilitates rapid 
translation of molecular discoveries to clinical use136. TMAs are applicable for 
molecular methods such as FISH and immunohistochemistry137,138, for this 
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method it is only a very small cylinder of 0.6mm diameter of presumed 
representative tumour tissue that is investigated. Using a larger number of 
cylinders may lead to increased detection of amplified regions; although it is 
also associated with additional work and tissue consumption, and may also lead 
to statistical challenges if unequal amounts of tissue spots are analysed per 
tumour139. One study on HER2 amplification, ERα expression and PR 
expression, suggests that increasing the number of cylinder cores will reduce 
the non-concordance between whole tissue sections and TMAs140. Also when 
using TMAs it is difficult to optimise conditions in terms of pre-treatment and 
enzyme digestion for each tissue section, which means that for a certain 
percentage of the sections conditions are not optimal for analysis141,142.  
 
4.1.4 Sanger sequencing vs mass spectrometry genotyping 
 
Sanger sequencing is a well-established method and is applied routinely in 
clinical practice. For KRAS and BRAF mutation testing, Sanger sequencing is 
used to determine if patients should receive EGFR and BRAF inhibitors, in 
lung cancer, colorectal cancer and melanoma143-145.  This sequencing method is 
also widely used in research for detection of point mutations and SNP 
typing146. In paper I and paper III we used Sanger sequencing to search for 
KRAS and PIK3CA point mutations in DNA extracted from primary and 
metastatic endometrial carcinoma lesions.  The disadvantage with Sanger 
sequencing is that the amount of tumour tissue should be above 30% to reduce 
the risk of false negatives, which may relate to presence of stromal 
contamination. This could be a challenge were the amount of sample available 
is limited. In colorectal cancer a study by Malapelle et al argues that Sanger 
sequencing is better to detect KRAS mutations in higher-grade cancers and 
metastatic lesions than in lower grade tumours, due to higher intra tumour 
heterogeneity and more stromal tissue contamination in lower grade 
tumours147.  A study of melanoma patients tumour samples further illustrates 
the challenge with tumour heterogeneity: Dividing FFPE sections into six parts 
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that were analysed for NRAS mutations, showed that three segments had NRAS, 
while the rest were negative148. Another challenge with Sanger sequencing is 
that it can only characterize rather short sequences (300-1000bp), due to the 
issue of separation of large sequences by one base pair149.   
In paper II we use a different method for mutation detection called Oncomap. 
Oncomap is based on the MassExtend reaction combined with MALDI-TOF 
MS (matrix assisted desorption/ionization mass spectrometry). The 
MassExtend reaction and MALDI-TOF MS is often referred to as the 
MassARRAY sytem and is commersialised through a company called 
Sequenome150-152. The MassExtend process consists of a post-PCR multiple 
primer extension in the presence of dideoxynucleotides (ddNTP´s) and 
deoxynucleotides (dNTP´s) in a 3:1 ratio150. The lack of the 3´-OH group on 
the ribose of ddNTPs stops the PCR reaction, since no phosphodiester bond can 
be formed. This results in allele specific terminated extension fragments, which 
then can be separated in a mass spectrometer. The predominant advantage with 
mass spectrometry is the direct detection of the analyte itself, avoiding use of 
tags such as fluorochromes153.  Another advantage especially in cancer research 
is that in a sample of high allelic heterogeneity, mutations can still be detected.  
The Mass Extend together with MALDI-TOF reaction allows for the detection 
of allelic ratios as low as 1:50153.  The ability to perform multiplexing by 
analysing several extended primers simultaneously is also an advantage. 
Whereas for Sanger sequencing this would be impossible where the separation 
of terminated sequences in a poly-acrylamide is the basis of analysis. Still, the 
Oncomap method only allows detection of already reported mutations included 
in the panel, and updated versions including a large range of potentially 
therapy-relevant mutations in oncogenes are presently offered as part of the 
molecular tumour classification at some comprehensive cancer centres154,155.  
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4.1.5 Connectivity map 
 
Connectivity Map is a method to systematically approach functional 
connections between small molecule therapeutics, disease, and gene expression 
data156. A database containing gene expression signatures from three cell lines 
(MCF7 (breast cancer), PC3 (prostate cancer) and HL60 (leukaemia) treated 
with 1309 different drugs has been developed. The expression signatures 
provided in the database reflect the gene expression changes related to each 
drug in the individual cell line. Researches can then use generated signatures 
related to their own research and compare these with the signatures in the 
Connectivity Map database to obtain functional connections in signalling 
pathways or use the database for drug discovery156.   
During the experimental process of paper I we generated gene signatures based 
on patients with KRAS amplifications and KRAS mutations. We used the 
Connectivity Map to identify compounds whose gene signatures were anti-
correlated with gene expression patterns for patients from these two cohorts 
(see table 4).  
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Table 4. Compounds with gene signatures anti-correlated to KRAS 
amplification and KRAS mutation signatures. 
 
KRAS amplification 
Rank Name of compound  N* P-value† Known function 
1 Wortmannin 18 < 0.001 PI3K inhibitor 
2 AnisoMYCin 4 < 0.001 Protein synthesis inhibitor 
3 Podophyllotoxin 4 < 0.001 Topoisomerase II-inhibitor 
4 Guanabenz 5 0.001 α-adrenergic receptor inhibitor 
5 Lycorine 5 0.001 Protein synthesis inhibitor 
6 Monensin 6 0.002 Antibiotic 
7 Thapsigargin 3 0.004 SERCA-inhibitor 
8 Tranexamic acid 5 0.004 Plasminogen inhibitor 
KRAS mutation 
1 LY-294002 61 < 0.001 PI3K-inhibitor 
2 Cephaeline 5 < 0.001 Antiphsycotic 
3 Sanguinarine 2 < 0.001 Ion-channel inhibitor 
4 Tolazoline 5 0.0017 α-adrenergic receptor inhibitor 
5 Harmine 4 0.002 monoamine oxidase A inhibitor 
6 Emetine 4 0.003 Anti protozoal  
7 Etofenamate 4 0.004 Anti-inflammatory 
8 Apigenin 4 0.004 CYP2C9-inhibitor 
 
N = number of instances in which the compounds were tested in the Connectivity map. 
 
†The p-value for each small molecule represents the distribution of these scores compared with the distribution of scores among all 
small molecules, using a permutation test as described by Lamb et al (2) 
3 By SNP-array 
 
 
The most anti correlated gene signatures were related to the PI3K inhibitors 
wortmannin (KRAS amplification) and LY-294002 (KRAS mutation)157,158. 
These results indicate that wortmannin could be used to reverse the effects of 
KRAS amplification and mutation in endometrial cancer. However, further 
testing in a clinical trial setting is needed. 
In paper III we used Connectivity Map to search for compounds whose 
signatures were anti-correlated with the MYC signalling signature and the top 
50 under- and over-expressed genes in patients with metastatic disease 
compared to patients without metastatic disease. The MYC signalling signature 
and the gene set related to metastatic disease were both most anti correlated to 
the signature of Tricostatin A, a HDAC inhibitor (see table 5).  
 
 
 
 
 DD
Table 5. Compounds with gene signatures anti-correlated to metastatic 
disease or the MYC signalling signature   
 
Anti-correlated to the MYC signaling signature 
  
Rank Name of compound N* p-value† Known function 
1 LY-294002 61 <0.00001 PI3-Kinase inhibitor 
1 sirolimus 44 <0.00001 mTOR inhibitor 
1 tanespiMYCin 62 <0.00001 heat shock protein 90 inhibitor 
5 trifluoperazine 16 0.0006 antipsychotic drug 
6 metyrapone 4 0.0007 steroid 11β-hydroxylase inhibitor 
7 latamoxef 3 0.0001 oxacephem antibiotic  
8 3-acetylcoumarin 5 0.001  
9 wortmannin 18 0.001 PI3-Kinase inhibitor 
10 vorinostat 12 0.003 HDAC inhibitor 
     
Anti-correlated to a gene signature defined by genes differentially regulated in patients with 
metastatic disease compared with patients without metastatic disease 
1 puroMYCin 182 <0.00001 Protein synthesis inhibitor 
1 cicloheximide 61 <0.00001 Protein synthesis inhibitor 
1 trichostatin A 44 <0.00001 HDAC inhibitor 
1 sirolimus 62 <0.00001 mTOR inhibitor 
1 LY-294002 16 0.0006 PI3-Kinase inhibitor 
6 wortmannin 4 0.0007 PI3-Kinase inhibitor 
7 thioridazine 3 0.0001 Antipsychotic drug 
8 cephaeline 5 0.001 alkaloid chemical 
9 vorinostat 18 0.001 HDAC inhibitor 
10 trifluoperazine 12 0.003 Antipsychotic drug 
     
* N = number of instances in which the compounds were tested in the Connectivity map  
†The p-value for each small molecule represents the distribution of these scores compared with the distribution of scores among 
all small molecules, using a permutation test as described by Lamb et al (2) 
 
 
Even though Connectivity Map can provide very useful information it has its 
limitations. In our case of drug discovery we know that the database is 
generated using cell lines of a different origin than endometrial cancer, which 
may influence the results. Cell lines grown in a plastic container in a lab do not 
resemble the complexity of cancer in vivo and hence effects on gene 
expression caused by the tumour microenvironment are not accessible to mine 
from Connectivity Map. However, as a hypothesis generating tool Connectivity 
Map may be very useful, and is less labour intensive and costly compared to 
using drug libraries and loss of function studies such as siRNA arrays.  
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4.2 Discussion of results. 
 
In the context of cancer, a biomarker is something that is objectively measured 
reflecting the biologic-, pathogenic- or pharmacologic responses to a 
therapeutic intervention, as defined by the Biomarkers Definitions Working 
Group32. Biomarkers are further classified according to their application as 
prognostic- or predictive marker.  Prognostic biomarkers provide information 
on the course of disease, while predictive biomarkers are applied to measure 
response to specific treatment32. Some biomarkers may be markers for a 
biologic process driving the carcinogenic- and metastatic process and thus poor 
outcome and also represent a therapeutic target that may predict response to 
targeting therapy. It is a challenge to separate the prognostic- from the 
predictive impact of such markers in retrospective studies, and usually 
randomized controlled clinical trials exploring targeting drugs in relation to 
outcome will be needed to separate the prognostic- from the predictive impact 
of a biomarker159. 
One relevant example illustrating this challenge in endometrial carcinoma is 
the fact that some, but not all PIK3CA alterations are linked to PI3K activation 
and aggressive disease81,160. It is unsettled if any of the prognostic or other 
markers for PIK3CA alterations may be applied to predict response to drugs 
targeting the PI3K/mTOR/AKT signaling pathway 161.  Also ligands binding to 
receptor tyrosine kinases such as EGFR, HER2 and FGFR2, may lead to the 
activation of PI3K162-164. The tumour suppressor phosphatase and tensin 
homolog (PTEN), known to be frequently altered in endometrial cancer, 
counteracts this activation114,165. PI3K is also known to be activated by 
RAS166,167.  An increased understanding of cell signalling in endometrial cancer 
is critical for the development of new biomarkers and therapy, both related to 
PI3K signalling as well as other signalling pathways (see figure 5).  
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Figure 5. Potential drugable targets in endometrial cancer 
 
4.2.1 Gene amplification and mRNA expression as prognostic markers in 
endometrial carcinoma 
 
Several studies have shown that amplification of specific genes or gene copy-
number variations affect the prognoses of endometrial cancer patients79,81,168,169. 
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In paper I we show that KRAS amplification is associated with metastatic 
disease in endometrial cancer, and that KRAS mRNA expression is also 
increased in cases with KRAS amplifications. KRAS amplification could be 
used as a prognostic marker in endometrial cancer, as this marker maintained 
its independence in Cox multivariate analysis adjusted for age, histological 
subtype and FIGO stage. However due to the low number of patients identified 
to have copy number alterations by FISH and the methodological challenges, 
the true clinical value for implementation would most likely be low.  
In paper III we show that amplification of MYC and over-expression of 
ATAD2 is related to poor prognosis in endometrial cancer.  Over-expression of 
ATAD2 could serve as a prognostic marker, as ATAD2 maintains its 
independence in a Cox multivariate analysis adjusted for ER-status also 
consistently found to be a robust prognostic marker in endometrial 
carcinoma38. We have explored an antibody detecting ATAD2 protein for 
overlap with mRNA expression levels and in relation to clinical data, and 
preliminary results show the same trends (data in progress). Still, a robust 
immunohistochemical marker to be applied in FFPE tissue needs to be further 
developed and validated before routine application may be feasible.  
 
4.2.2 Gene mutations as prognostic markers in endometrial carcinoma 
 
In our papers we use Sanger sequencing for mutation detection (papers I and II) 
and mass spectrometric genotyping (paper II) to screen for mutations in known 
oncogenes.  
 
In paper I and paper II we find that KRAS is mutated in 14.7 and 17.9% of 
endometrial cancer patients. The frequency level of 14.7 % and 17.9% is 
consistent with other studies100,160,170-172. The difference we find in frequency 
between paper I and paper II, is most likely due to the additional investigation 
of KRAS codon 61 in paper II where we found one mutation. 
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In paper I we do not find a direct link between KRAS mutations and prognosis, 
also described by others101,160. However a study by Byron et al states that KRAS 
mutations associate with longer disease free survival in early stage endometrial 
cancer100. This supports our findings that there is a significant correlation 
between KRAS mutation and lower grade endometrioid tumours, and is also in 
line with reports on KRAS mutations in hyperplasias with atypia, considered to 
be precursor lesions for endometrioid tumours101,173.  Although it seems that 
KRAS mutations in general is related to less aggressive endometrial cancers, we 
find in a subgroup analysis of the different base pair substitutions, that some 
tended to associate with poor prognosis. The G13D mutation especially showed 
a worse prognosis, although not statistically significant. Probably related to the 
low sample size in the subgroup analyses. It should be considered in future 
analysis of KRAS that the different base pair substitutions and subsequently 
amino acid changes within exon 2 might affect the phenotype in endometrial 
cancers harbouring KRAS mutations.  
 
Of the mutations explored in paper II, the most frequently mutated oncogene 
was FGFR2 present in 10.4% of tumours, in line with the initial reports from 
Byron et al, Dutt et al and Pollock et al93,100,174. Byron et al reports that patients 
with early stage tumours (stage I and II) and FGFR2 mutations have shorter 
disease free survival time, suggesting that FGFR2 could be used as a 
prognostic factor in early stage cancers, although this finding has not been 
consistent and needs further validation100.   
 
The third most frequently mutated gene detected was PIK3CA (11.9%). 
PIK3CA is reported as the second most frequently mutated oncogene in 
endometrial cancer after PTEN (approximately 23% for all exons, Cosmic)116. 
However in endometrial cancer the exons 9 and 20 of PIK3CA is the main 
location of mutations. Although PIK3CA mutations was not linked to a special 
phenotype in our study, a recent study has shown that PIK3CA H1047R 
mutation might predict poor prognosis in grade I and II patients160.  Other 
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studies relate PIK3CA mutations in endometrial cancer to low stage, high grade 
and invasive tumours175,176.  Nevertheless further studies are needed on the 
prognostic value of PIK3CA mutations in endometrial cancer.  
 
4.2.3 Oncogenes as predictive markers for response to targeting therapies 
in endometrial cancer 
 
In current cancer treatment mutational testing may serve as predictive markers 
for therapy. Genetic mutations could both serve as markers for targeting 
therapy such as BRAF V600 for vemurafenib in malignant melanoma, or they 
could predict resistance to drugs such as KRAS mutations for EGFR antibody 
inhibitors as cetuximab and panitumumab in colorectal cancer177-180. Mutations 
in the EGFR gene itself predict response to small molecule EGFR inhibitors 
such as erlotinib and gefitinib in lung cancer181,182. Recently, also presence of 
PIK3CA mutations indicated sensitivity to PI3K pathway inhibitors with higher 
response rates, 39% versus 10% after failure with standard treatment in 
gynecologic cancers183. KRAS, PIK3CA, EGFR and BRAF were all tested for 
mutations in paper II.  However, mutational testing is not performed routinely 
in endometrial cancers since none of the available targeted therapeutics has 
been shown to be effective in clinical trials at present27,39. Also, mechanisms 
related to chemotherapy resistance are poorly understood and predictive 
markers for response are not available27. 
 
In paper II we wanted in particular to compare the presence of mutations in 
known oncogenes in primary and metastatic endometrial cancer lesions. For 
several of these alterations, targeted therapy has been developed and are 
approved for clinical use in other cancer types177,184.  
 
In paper II we found that the most frequent single mutation was FGFR2 
S252W. FGFR2 signalling has been implicated in endometrial cancer 
progression, although the prognostic value of FGFR2 is still debated, however 
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these studies show the potential of FGFR2 inhibition in endometrial cancer. 
Several studies have shown that endometrial cancer cell lines with FGFR2 
mutations respond to FGFR2 inhibition93,185.  Another aspect of FGFR2 in 
endometrial cancer treatments is that FGFR2 inhibition seems to sensitize 
endometrial cancer cells to standard chemotherapeutic agents such as paclitaxel 
and doxorubicin. This has been shown in both FGFR2 mutated and FGFR2 
wild type endometrial cancer cell lines, indicating that not only could FGFR2 
mutations be used as a predictive marker for FGFR2 inhibition alone, but also 
for standard chemotherapy in endometrial cancer186.    
 
The PI3K/mTOR pathway is frequently activated in endometrial cancer where 
activating mutations in PIK3CA and inactivating mutations in PTEN are 
considered to be important187. Targeting this pathway is suggested in several 
studies, and clinical trials are in progress27,81. In paper II we find that PIK3CA 
is mutated in 11.9%.  PIK3CA mutations have been suggested as predictive 
markers for PI3K/AKT/mTOR inhibitors in endometrial cancer and breast 
cancer183. PIK3CA mutations has also recently been shown to predict resistance 
to HER2 inhibition in breast cancer, which could explain the low efficacy of 
HER2 inhibition in endometrial cancer188. However, further studies are needed 
to elucidate the predictive value of PIK3CA mutations in endometrial cancer. 
 
Mutation testing of KRAS is already in use in the clinic as a predictive marker 
for EGFR inhibitor response in colorectal cancer189. In endometrial cancer 
EGFR inhibition therapy has not proven to be efficient. However in the clinical 
trials conducted, KRAS mutations was not tested for39.  In endometrial cancer 
cell lines treated with the dual PI3K/mTOR inhibitor NVP-BEZ235 and the 
mTOR inhibitor RAD001, KRAS mutations predicts resistance. By using a 
mitogen-activated-kinase-kinase (MEK) inhibitor (PD98059 or UO126) KRAS 
mutated cell lines were sensitized to PI3K/mTOR inhibition190.  As mentioned 
the specific base pair substitutions in mutated KRAS may affect prognosis, 
interestingly this has also been shown to affect KRAS´s predictive properties to 
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EGFR inhibition. A study on metastatic colorectal cancer demonstrated that 
patients harbouring KRAS G13D mutations had a worse prognosis, they also 
responded to EGFR inhibitors191.  
 
We also found single mutations in BRAF, NRAS, HRAS and EGFR. Although 
the frequency level of these mutations was low, they could play roles in the 
tumorigenesis for subgroups of endometrial cancers when present. Especially 
mutations in EGFR and BRAF are interesting due to developed inhibitors 
already introduced for clinical use in lung cancer and melanoma. No mutations 
showed increase from primary to metastatic lesions, although the sample set 
explored was small in our study.  
 
4.2.4 Gene amplification and mRNA over-expression as predictive 
markers in endometrial cancer 
 
In our studies we investigated the impact of MYC and KRAS amplifications in 
relation to endometrial cancer phenotypes. From the data generated by using 
Connectivity Map we find that patients with KRAS amplifications could 
potentially be treated with PI3K inhibitors. KRAS is known to activate PI3K, 
hence inhibition of PI3K may also be biologically plausible for patients with 
KRAS amplification84,192,193. Drug targets related to PI3K signalling has been 
suggested as promising targets for new therapeutics in endometrial cancer, also 
evidenced by the distribution of drugs tested in phase I and phase II clinical 
trials for this disease27. Whether presence of KRAS amplification predicts 
response to therapy targeting PI3K signalling needs to be further explored.   
 
Due to recent reports which have shown that KRAS amplifications, although to 
less extend than KRAS mutations, are related to resistance to EGFR inhibition 
in colorectal cancer194,195, we speculated that we might find drugs related to 
EGFR inhibition when mining the Connectivity Map. However, we none of the 
drugs related to EGFR inhibition were amongst the most promising drugs from 
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the analyses. Based on this, one may speculate that KRAS signals through 
PI3K, rather than through the classical EGFR-MAP-kinase pathway, is 
important in endometrial cancer196,197. Apparently contradictory to our results 
in table 4, KRAS amplified endometrial cancer cell lines have been shown to 
predict resistance to PI3K/mTOR inhibition, and further studies in clinical 
trials are needed 190.  
 
Our results also suggest that ATAD2 over-expression due to 8q.24 
amplification should be further explored as a predictive marker for the HDAC 
inhibitor Tricostatin A in MYC dependent endometrial cancers198. Several other 
studies on endometrial cancer cell lines have shown effects of HDAC 
inhibitors. Yi et al have shown that a combination of HDAC and DNA methyl-
transferase inhibitors reduce growth in RL-952 and Hec1B endometrial cancer 
cells, by up-regulating E-cadherin, a protein needed for cell-cell attachment, 
and down regulation of the anti- apoptotic protein Bcl-2199-201. Another study 
on Ark2, Ishikawa, and AN3 endometrial cancer cells treated with the HDAC 
inhibitor oxamflatin showed induction of apoptosis202. The combination of 
paclitaxel and tricostatin-A has also been shown to have a synergistic effect, 
resulting in apoptosis in the endometrial cancer cell lines Ark2 and KLE. These 
effects were also confirmed in a mouse xenograft model for the Ark2 cell 
line203. A study on Hec-1A and ECC-1 reports that tricostatin-A downregulates 
the expression of MYC, which again increase the expression of p21 (cyclin 
dependent kinase inhibitor 1) and the pro apoptotic protein Bim (Bcl-2 
interacting protein) leading to regulated cell death204.  Interestingly the 
compound 2nd most anti-correlated to the MYC signalling signature were the 
PI3K inhibitor LY294002 (see table 5). In a recent study it was reported that 
HDAC inhibitor OBP-801/YM753 together with PI3K inhibitor LY294002 
synergistically induces apoptosis in endometrial cancer cells in a Bim and ROS 
(reactive oxygen species) dependent manner205.  The same synergistic effects 
of PI3K and HDAC inhibitors have been shown in T-cell lymphoma, non-small 
cell lung cancer (NSCLC) and chronic myeloid leukemia (CML)206,207. 
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The results from paper III may thus suggest that HDAC inhibitors may be of 
particular relevance for MYC dependent endometrial cancers, and that 8q24 
amplification and ATAD2 over-expression may represent potential predictive 
markers for response, although further testing in controlled clinical trials is 
needed to explore the clinical relevance of this observation.  
 
4.2.5 How representative are molecular findings in the primary tumour 
for metastatic disease? 
 
In endometrial cancer the primary tumour is removed by surgery, although 
when the disease spread and form distant secondary tumours, these are almost 
impossible to surgically remove and the patient is classified to have systemic 
disease. The spreading of cells in the body through blood- and lymph vessels 
results in physical obstruction, competition with normal cells over nutrients and 
oxygen, and interference with normal organ function50. Today there is usually 
no cure for distant metastatic disease unless surgically resectable in 
endometrial cancer.  Thus, there is an urgent need to improve systemic 
therapies and improve the understanding of relevant targets for new treatment 
in metastatic endometrial carcinomas in particular208. Comprehensive 
molecular profiling of primary endometrial carcinomas has been one major 
effort to improve our understanding40,81,209. Still, the question regarding how 
well the primary tumour reflect the potential targets in metastatic lesions, is to 
date less well explored, but comprehensive studies in renal carcinoma has 
recently demonstrated that molecular alterations in different lesions may show 
substantial heterogeneity210. Interestingly we show that the rate of KRAS and 
MYC amplifications increase in metastatic lesions compared to the primary 
tumour (paper I and paper III). In breast cancer MYC gene amplification has 
been shown to be acquired in metastatic lesions of unamplified primary 
tumours211. Similar events has been reported for HER2 in breast cancer212. 
However we also find that in some of the metastatic lesions there is a loss in 
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gene copy-number of KRAS and MYC, which may also be related to tumour 
heterogeneity and ability for the method to detect amplifications. In a case 
study of HER2 inhibitors in endometrial cancer, one patient with a HER2 
positive primary tumour three years later developed a lung metastasis that 
apparently was HER2 negative, demonstrating that a primary tumour could 
give rise to metastatic lesions with different genetic characteristics213. In a 
clinical setting information of the molecular characteristics of metastatic 
lesions may be of critical value when targeted therapy is applied. This is further 
actualized by the fact that 90% of deaths in solid tumours is caused by 
metastatic lesions50. A challenge is that many of the metastatic lesions and the 
palliative setting will restrict access to representative and fresh metastatic 
lesions needed for comprehensive molecular profiling.  
 
Little is known about clinical relevance for discrepancy in molecular findings 
for primary- and metastatic endometrial carcinoma lesions. However, in 
colorectal cancer this has been more studied and debated. Patients with KRAS 
codon 12/13 mutations in the primary tumour will normally not be given EGFR 
inhibitors as KRAS codon 12/13 mutations associate with poor response to 
therapy, even though the metastatic lesions might be KRAS wild type214. It has 
also been reported in colorectal cancer that KRAS mutation status in lymph 
node metastasis are more discordant to primary tumour than what is seen for 
liver metastases215. This appears to be in line with our data showing that 
patients with multiple metastases may have different mRNA expression and 
unique changes in copy-number alterations for the individual metastatic 
lesions. Whether this is related to sampling or methodological challenges or 
tumour clonal differences is critical for targeting therapy in a metastatic setting, 
and will need to be further explored. When testing targeted therapy in clinical 
trials, it will be important to explore if the metastatic lesions have different 
molecular characteristics from the primary lesions for the presumed target of 
the drug, to fully explore efficacy related to biomarker status216.  
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4.2.6 Biologic significance of identified genetic changes 
 
A single cancer cell can develop thousands of genetic changes, including point 
mutations, copy number variations and translocations. However, the majority 
of these are not believed to affect tumour development, and are considered to 
be passenger mutations217. It is critical to identify the genetic changes that drive 
the processes of tumorigenesis to identify new critical targets for treatment218.  
 
Are KRAS alterations driving endometrial cancer progression? 
 
KRAS mutation has been suggested as an early event in endometrial cancer due 
to the detection of KRAS mutations in endometrial hyperplasias219. With 
regards to prognosis, patients harbouring KRAS mutations do not present with 
any clear phenotype. However, due to mutated KRAS role in tumour initiation 
of pancreatic cancer and tumour proliferation ´in colorectal cancer, we could 
speculate that mutated KRAS might also exhibit similar functions in 
endometrial cancer220,221. In paper I it was important to search for mutations in 
KRAS to identify or exclude a link to KRAS amplifications. We found that 
KRAS amplifications and KRAS mutations are almost mutually exclusive. 
Apparently in line with this, for colorectal cancer it has been found that KRAS 
amplification is mutually exclusive to KRAS mutations195. However, in lung 
cancer KRAS amplification and KRAS mutations seems to act synergistically to 
promote tumour progression222.  Studies of KRAS mutations in endometrial 
hyperplasias and processes related to tumour progression are scarce and the 
number of samples used is low, and further research is needed and in progress 
in our group. 
  
For KRAS amplification we show this to be related to poor prognosis in 
endometrial cancer patients. This discrepancy between mutation status and 
amplification emphasises that KRAS role in tumour progression needs to be 
elucidated. Is KRAS amplification a driver in endometrial cancer? In our study 
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this might be indicated by the increase of KRAS amplification and mRNA over-
expression from primary tumours to metastatic lesions. We also find that Ets2 
is significantly differentially expressed in patients harbouring KRAS 
amplifications (paper I). Ets2 is a transcription factor indirectly activated by 
Erk1/2 through the phosphorylation of Ets2 repression factor (ERF)223.  Ets2 
has also been linked to colon cancer tumorigenesis224.  
 
We also show that KRAS amplification and over-expression is related to 
aneuploidy and p53 over-expression.  Tumour protein 53 (TP53) over-
expression, which is a marker for p53 mutations, has been related to 
aneuploidy in several cancer types225,226. KRAS amplifications might be a result 
of p53 mutations and a general unstable genome, which on the other side lessen 
the chance of KRAS amplification being the driver gene of this patient group 
due to a general chromosomal imbalance. Whether KRAS alterations are drivers 
in endometrial cancer still remains an open question.  
 
Is ATAD2 a driver in MYC dependent endometrial cancer? 
 
We show that amplification of the 8q.24 region and MYC is associated with 
aggressive and metastatic endometrial cancer. ATAD2 is the gene with highest 
mRNA expression of all genes within the 8q.24 amplicon, and has a higher 
MYC signalling score than MYC itself, not only in endometrial cancer, but also 
in glioblastoma, breast cancer and ovarian cancer.  We believe that this is a 
result of the abilities of ATAD2 to act as a cofactor for MYC. This has also 
recently been described in lung cancer and in lung cancer cell lines227,228. To 
explore the biologic properties of ATAD2 in MYC dependent cancers we used 
shRNA to knock down the mRNA expression. Knockdown of MYC and 
subsequently ATAD2 resulted in decreased viability in the seven endometrial 
cancer cell lines tested. This support that cell lines dependent on MYC is also 
dependent on ATAD2. However, further testing is needed to elucidate the 
properties of ATAD2 as a driver in endometrial cancer in a clinical context. 
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 Gene amplification vs. point mutations in relation to endometrial cancer 
phenotype. 
 
In papers I and III, we describe that amplifications of KRAS and MYC 
associated with poor prognosis and increase from primary to metastatic lesions 
in endometrial cancer. In paper II exploring distribution of mutations in known 
oncogenes, we show that point mutations do not seem to affect prognosis, nor 
increase from primary to metastatic lesions as shown for gene amplifications.  
 
Figure 6. Suggested model for endometrial cancer development. 
Abbreviations: Mut = mutation, ME = methylation, AMP = amplifaction, OE = over-expression. 
 
Several of the most common mutations detected in endometrial carcinomas as 
PTEN and KRAS have also been detected in the presumed precursor lesion 
hyperplasia with atypia and are reported to be enriched in the more favourable 
endometrioid and lower grade tumours219,229. This is contrasting the findings 
for TP53 over-expression a surrogate marker for TP53 mutation; being linked 
to non-endometrioid histology, metastatic disease and unfavourable 
outcome160,230.  
 
This may suggest that it is the development of chromosomal instability and 
gene amplifications that links to the metastatic process and poor prognosis, 
more than genetic defects as point mutations possibly caused by microsatellite 
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instability and POLE mutations, where the latter may be more critical for the 
earlier events in the carcinogenic process (see figure 6)40,215,231.  However, 
point mutations or methylation of DNA repair genes might be the cause of 
chromosomal instability232.  
 
5. Conclusions 
 
1. KRAS amplifications and KRAS mRNA over-expression increase from 
primary to metastatic lesions, and may be drivers in the progression of 
endometrial cancer (paper I). 
2. KRAS mutations are associated with endometrioid and non-aggressive 
endometrial cancer (paper I).  
3. FGFR2, KRAS and PIK3CA are frequently mutated in primary 
endometrial cancer lesions, and are suggested as targets for therapy 
although no increase is seen in metastatic lesions (paper II). 
4. ATAD2 mRNA over-expression and MYC amplification associates with 
aggressive endometrial cancers (paper III). 
5. HDAC is a suggested target in ATAD2 over-expressing endometrial 
cancers. 
6. ATAD2 is important in MYC dependent cancers. 
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6. Future perspectives 
 
In our studies we have investigated mutation status, gene copy-number 
variations, and mRNA expression levels for selected genes in relation to 
clinical phenotype in endometrial cancer.  
 
To further assess KRAS status in endometrial cancers, a more applicable 
protein marker for expression of KRAS, in relation to KRAS amplification, 
mutation and mRNA over-expression should be explored to be able to assess 
KRAS status in FFPE tissues more readily available in standard clinical care. 
Such development of more robust and applicable biomarkers will be 
important. This also apply for FISH probes, and our studies suggest that robust 
probes for MYC, KRAS and ATAD2 may be relevant for routine clinical use and 
for further explorative studies in specimens from randomized clinical trials. 
 
Resources like TCGA (The Cancer Genome Atlas) and COSMIC (Catalogue of 
somatic mutations in cancer) will be of great value in future research to help 
define additional promising targets for further preclinical studies and 
assessment in clinical samples.  
 
Improved pre clinical models are also needed to better understand 
mechanisms involved in endometrial cancer when applying PI3K, FGFR2 and 
KRAS related inhibitors and other drugs.  
 
Relatively few endometrial cancer cell lines are commercially available for 
preclinical studies. There is a need to develop more cell lines also resembling 
non-aggressive endometrial cancer. The majority of cell lines currently 
available resemble very aggressive endometrial cancers. Development of non-
aggressive cell lines could provide valuable information in terms of 
endometrial cancer initiation. There is also a need to implement new cell line 
techniques. The most common practice in cell line studies is to grow cells as a 
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monolayer in culture flasks. By using 3D systems such as growing cells in a 
designed extracellular matrix which can be manipulated in almost unlimited 
ways, relevant knowledge about motility, invasiveness, and drug response 
might be more clinically relevant.  
 
Very few mouse models have been developed in endometrial cancer, and those 
develop have been dominated by cell lines and not orthotopic models 
developed from clinical samples. Only few mouse models are designed to 
explore the role of specific genes or pathways in endometrial carcinoma233. A 
larger spectre of mouse models would not only be valuable to study 
endometrial tumour progression, but also represent models for more relevant 
studies linking targets to response to targeted therapeutics. 
 
Most therapies classified as targeted, target proteins. However, the majority of 
large-scale molecular studies conducted in endometrial cancer involve DNA or 
mRNA. Large-scale proteomic studies in endometrial cancer may represent 
an important additional layer of understanding for potential novel treatment 
strategies in this disease.  
 
Furthermore, the majority of studies on molecular markers in endometrial 
cancer are assessed in primary tumours. An increased focus on metastatic 
lesions is essential for the validation of relevance for new potential biomarkers 
in a systemic disease setting. There is increasing evidence that metastatic 
lesions develop different molecular characteristics compared to the primary 
tumour during carcinogenesis adding to the complexity in targeting specific 
molecular alterations detected in one primary lesion with systemic disease.  
Thus, to increase our understanding for the metastatic process, molecular 
profiling of metastatic- compared to primary lesions will also be important 
to elucidate critical factors involved in the initiation of endometrial cancer and 
their connection to the metastatic process, to be further explored in relevant 
preclinical models and clinical trials.  
 FA
 
Novel imaging techniques such as PET-CT needs to be explored in relation to 
molecular subtypes in endometrial cancer and for their potential of early 
detection of response to therapy. There is also a need to develop new cancer 
specific and biology specific tracers in addition to 18F-fluorodeoxyglucose 
(FDG), which at an early stage could indicate targets of therapy. 
 
A large number of costly randomized clinical trials of targeted therapies have 
failed to show efficacy. Inclusion of more comprehensive molecular 
characterization of sequential biopsies in clinical trials may offer important 
knowledge regarding resistance mechanisms and markers for response 
prediction. So far, funding related to such translational studies in clinical trials 
have been difficult to secure, although increasingly focused in the scientific 
and public discussions. Policy change with a stronger demand for 
comprehensive translational studies to be included for approval of clinical trials 
may be important to promote this.  
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Paper I 

KRAS gene amplification and overexpression but not mutation
associates with aggressive and metastatic endometrial cancer
E Birkeland1,2, E Wik1,2, S Mjøs1,2, EA Hoivik1,2, J Trovik1,2, HMJ Werner1,2, K Kusonmano1,2,3, K Petersen3,
MB Raeder1,2, F Holst4, AM Øyan5,6, K-H Kalland5,6, LA Akslen5,6, R Simon4, C Krakstad1,2 and HB Salvesen*,1,2
1Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen 5021, Norway; 2Department of Clinical Medicine, University of
Bergen, Bergen 5020, Norway; 3Computational Biology Unit, Uni Computing, Uni Research AS, Bergen 5008, Norway; 4Department of Pathology,
University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany; 5The Gade Institute, University of Bergen, Bergen 5020
Norway; 6Department of Pathology, Haukeland University Hospital, Bergen 5020, Norway
BACKGROUND: Three quarter of endometrial carcinomas are treated at early stage. Still, 15 to 20% of these patients experience
recurrence, with little effect from systemic therapies. Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue (KRAS)
mutations have been reported to have an important role in tumorigenesis for human cancers, but there is limited knowledge
regarding clinical relevance of KRAS status in endometrial carcinomas.
METHODS: We have performed a comprehensive and integrated characterisation of genome-wide expression related to KRAS
mutations and copy-number alterations in primary- and metastatic endometrial carcinoma lesions in relation to clinical and
histopathological data. A primary investigation set and clinical validation set was applied, consisting of 414 primary tumours and
61 metastatic lesions totally.
RESULTS: Amplification and gain of KRAS present in 3% of the primary lesions and 18% of metastatic lesions correlated significantly with
poor outcome, high International Federation of Gynaecology and Obstetrics stage, non-endometrioid subtype, high grade,
aneuploidy, receptor loss and high KRAS mRNA levels, also found to be associated with aggressive phenotype. In contrast, KRAS
mutations were present in 14.7% of primary lesions with no increase in metastatic lesions, and did not influence outcome, but was
significantly associated with endometrioid subtype, low grade and obesity.
CONCLUSION: These results support that KRAS amplification and KRAS mRNA expression, both increasing from primary to metastatic
lesions, are relevant for endometrial carcinoma disease progression.
British Journal of Cancer (2012) 107, 1997–2004. doi:10.1038/bjc.2012.477 www.bjcancer.com
Published online 25 October 2012
& 2012 Cancer Research UK
Keywords: endometrial cancer; prognosis; KRAS; amplification; mutation
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Endometrial cancer is the most common pelvic gynaecological
malignancy in industrialised countries. Although 75% are treated
at an early stage, 15 to 20% recur. There is a need for more
effective systemic therapies, as no new targeted therapies are yet
available in standard clinical care, and response to conventional
systemic therapy is limited (Dedes et al, 2011). Several prognostic
markers exist, and recent studies have indicated promising new
targets to develop novel strategies for systemic therapies in
endometrial cancer (Salvesen et al, 2009). Still, no markers are
available to predict response to such therapy.
Traditionally, endometrial cancer has been divided into two
subgroups, type I and type II carcinomas, to assess the risk of
recurrent disease. Type I endometrial carcinoma is associated with
good prognosis, low grade, endometrioid morphology and rarely
metastasise to regional and distant sites (Fujimoto et al, 2009). Type
II endometrial carcinoma is associated with poor prognosis, non-
endometrioid histology and high grade. Still, there is considerable
overlap, and as tool to predict prognosis this classification may be
improved, as 20% of type I cancers recur and 50% of type II cancers
do not. Although the molecular alterations reported for type I and
type II cancers are overlapping, type I cancers are significantly more
often Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogene
(KRAS) and PTEN mutated, microsatellite instable, diploid and
expressing oestrogen- and progesterone receptors (ER, PR) (Lax
et al, 1998). Type II cancers, in contrast are more often aneuploid
and with altered expression of p53, p16 and with hormone receptor
loss. These differences are of prognostic value; nevertheless, the
molecular characteristics distinguishing Type I and Type II cancers
have so far had limited impact for tailoring systemic therapies.
Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogenes
homologue is a small GTPase and a member of the RAS
superfamily of proteins linked to the carcinogenic process in
preclinical models. Knock-down of KRAS in pancreatic cancer cell
lines leads to decreased motility and proliferation and a decreased
expression of pERK1/2, SNAIL and Nf-kB, all factors related to
epithelial to mesenchymal transition (Rachagani et al, 2011).
In colorectal cancer, KRAS has been reported to induce VEGF and
inhibit apoptosis through Akt phosphorylation under hypoxic
conditions (Zeng et al, 2010).
Activating KRAS mutations have been detected in precursor
lesions for colorectal and endometrial cancers indicating that these
*Correspondence: Dr HB Salvesen; E-mail: Helga.Salvesen@uib.no
Received 6 August 2012; revised 26 September 2012; accepted 26
September 2012; published online 25 October 2012
British Journal of Cancer (2012) 107, 1997–2004
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are early events (Dobrzycka et al, 2009). Mutations have been
found to have a prognostic impact in lung-, pancreatic- and
colorectal cancers (Gautschi et al, 2007; Ling et al, 2012).
In endometrial cancer, findings have been inconsistent, with
reported different prognostic impact for different age groups (Ito
et al, 1996; Semczuk et al, 1998). Furthermore, KRAS mutations
have been found to predict lack of response to EGFR inhibition in
lung- and colorectal cancers (Cepero et al, 2010). In endometrial
cancer trials of EGFR inhibitors have been limited, although some
studies reported partial response (Oza et al, 2008; Dedes et al,
2011).
Other measures for KRAS alterations, although less studied than
mutations, have supported a relevance of KRAS status for clinical
phenotype in cancer (Wagner et al, 2011). In lung cancer patients
with KRAS amplification and KRAS mutations, the latter only
associated with poor survival, but with no independent prediction
of response to therapy (Sasaki et al, 2011). Lung cancers
with KRAS amplification have been reported to have increased
expression levels of p21 (CDK1), suggesting an impact on cell cycle
regulation (Wagner et al, 2009). In endometrial cancers, one
previous study demonstrated a poor prognostic impact of
amplifications of the 12p12.1 region harbouring KRAS (Salvesen
et al, 2009). On this background, we have investigated several
aspects of KRAS alterations including mutation, amplification and
mRNA levels in relation to transcriptional alterations and clinical
phenotype. To study this, we have applied a unique sample set of
freshly frozen primary- and metastatic endometrial carcinoma
lesions as primary investigation set for a global and comprehensive
characterisation of molecular changes, and an independent, large
and extensively annotated patient series for validation of findings.
In particular, we wanted to investigate which KRAS alterations in
endometrial carcinoma that link to aggressive disease.
MATERIALS AND METHODS
Patient series
From May 2001 through 2009, freshly frozen and formalin-fixed
paraffin-embedded (FFPE) tissues have been prospectively
collected from primary- and metastatic endometrial carcinoma
lesions from patients treated at the Department of Gynaecology
and Obstetrics, Haukeland University Hospital, Bergen, Norway,
after collection of informed consent. In total 461 patients where
included for the various analyses in this study. Formalin-fixed
paraffin-embedded tumour tissue from hysterectomy specimens
from 414 primary tumours and 61 metastatic lesions were
mounted in tissue micro arrays (TMA) for amplification studies
of KRAS using fluorescence in situ hybridisation (FISH). DNA and
RNA were extracted from freshly frozen tissue from 264 primary-
and 22 metastatic lesions. Two hundred fifteen of these primary
tumours and all metastases were included in the FISH series.
Extracted DNA was used for SNP array- (74 patients) and mutation
analyses (264 patients), RNA were applied for micro-array
analysis (122 patients) and 161 patients were used for the qPCR
validation series. Primary tumour tissue in TMAs were analysed by
immunohistochemistry for ER, PR and p53 protein expressions
(461, 461 and 390 patients, respectively). The research has been
approved by the Norwegian Data Inspectorate (961478-2),
Norwegian Social Sciences Data Services (15501) and the Local
ethical committee (REKIII nr. 052.01). Women gave informed
consent.
Clinico-pathological data including age at diagnosis, Interna-
tional Federation of Gynaecology and Obstetrics (FIGO) stage
according to the 2009 criteria (FIGO IFoGaO, 1989; Mikuta, 1993),
histological subtype and grade, treatment and follow-up informa-
tion were available for all cases and were investigated in relation to
KRAS alterations.
Follow-up data regarding recurrence and survival were collected
from patient records and correspondence with physicians
responsible for outpatient care. Data were crosschecked with data
registered at the Norwegian Cancer Registry and Register for
Causes of deaths, Statistics, Norway. Date of last follow-up was
April 1st 2010. The median follow-up for survivors was 39 months
(range 2–90), 48 (12%) patients died because of endometrial
cancer during follow-up.
The therapy consisted of hysterectomy and bilateral salpingo-
oophorectomy unless surgery was contraindicated owing to
co-morbidity. Pelvic lymphadenectomy as part of surgical staging
was conducted after an overall assessment of the patients’
condition by the responsible surgeon as previously reported
(Trovik et al, 2011). Adjuvant therapy was recommended for
patients with FIGO stage XII and high-risk FIGO stage I patients,
defined as non-endometrioid tumours or deeply infiltrating
endometrioid grade 3 tumours. Of the 461 patients included in
our analysis 122 (26.4%) patients were given adjuvant treatment.
External radiation was given to 58 (12.6%), internal radiation to
2 (0.4%), chemotherapy to 54 (11.7%), anti-hormonal treatment to
5 (1.1%) and chemotherapy combined with radiation to 3 (0.7%)
patients.
Tissue micro-array construction
Haematoxylin and eosin-stained slides from individual tumour
specimens were evaluated to identify the area of highest tumour
purity. Tissue cylinders of diameter 0.6mm were punched out
from the selected areas for each corresponding paraffin block and
mounted into a recipient block using a custom-made precision
instrument (Beecher Instruments, Silver Spring, MD, USA). This
method has been described and its usefulness validated in several
earlier publications (Kononen et al, 1998; Engelsen et al, 2006).
The recipient blocks were treated at 40 1C for 20min and stored at
4 1C before 5 mm microtome sectioning for FISH analyses.
Representative tumour tissue was available in TMAs for FISH
from 414 hysterectomy specimens and from 61 corresponding
metastatic lesions of these patients.
Immunohistochemistry
Tissue micro array sections were dewaxed in xylene and
rehydrated in ethanol before microwave antibody retrieval.
The sections were incubated for 60min with p53 antibody
(Dako M7001, Copenhagen, Denmark), diluted 1:1000 and for
ER and PR as previously reported (Engelsen et al, 2008; Krakstad
et al, 2012). The staining was recorded as previously described
(Salvesen et al, 2000). In short, a semi-quantitative and subjective
grading system was used, and a staining index was calculated as a
product of staining intensity (0–3) and area of positive tumour
cells (1p10%, 2¼ 10–50% and 3X50%).
Copy-number assessment
For FISH analysis, TMA sections were incubated at 56 1C overnight
and treated according to the Paraffin Pre-treatment Protocol (Abbot
molecular, Wiesbaden, Germany). Hybridisation was performed
according to protocol from Abbot molecular. Briefly the sections
were dewaxed in xylene, dehydrated in 100% ethanol, air-dried and
treated with proteases for 12min, denatured and hybridised overnight
at 37 1C with KRAS/centromere enumeration probe (KRAS/CEP12q;
Abbot Molecular). Slides were washed with post hybridisation buffer
at 72 1C, counterstained with 40,60-diamidino-2-phenylindole (DAPI),
mounted, and stored in the dark before signal enumeration. For
FISH analysis, the slides were examined by Zeiss fluorescence micro-
scope (Go¨ttingen, Germany) equipped with a  63 oil immersion
objective. Each slide was scanned at low power with a DAPI filter
to recognise the TMA map. Areas of optimal tissue digestion and
KRAS status in metastatic endometrial cancer
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no overlapping nuclei were selected in each core for counting. In
each case, signals for probe and control were counted in 40–60
cells. Amplification of KRAS was defined as a final ratio obtained
for KRAS/CEP12q probes X2.0; KRAS gain was defined as KRAS/
CEP12q ratio41.0 but o2.0. Micrographs were taken from each
amplified spot, using the Zeiss Axiovision software. Copy-number
alterations assessed by SNP array were available for a subset of
74 patients from previous studies, and these data were applied
for analysis of KRAS copy-number alterations in relation to mRNA
expression levels in microarrays.
Oligonucelotide DNA microarray
The RNA was extracted using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) and hybridised to Agilent Whole Human
Genome Microarrays 44 k (Cat. no. G4112F) according to the
manufacturers instruction (www.agilent.com), and as previously
described (Krakstad et al, 2012). Microarray data have been
deposited in the ArrayExpress Archive database, http://www.ebi.
ac.uk/arrayexpress/ (ArrayExpress accession: E-MTAB-1007).
mRNA expression data of KRAS were obtained from DNA-
microarrays and a significance analysis of microarray (SAM) was
performed to investigate genes significantly differentially
expressed (FDR o0.05) in KRAS amplified compared with non-
KRAS-amplified tumours based on SNP-array data. The subset of
patients harbouring KRAS amplifications in FISH analyses with
available microarray data was to small to allow meaningful
statistical analysis (n¼ 3).
PCR and DNA sequencing
Genomic DNA was extracted from freshly frozen tissue samples
and investigated for point mutations in exon 2 codon 12 and 13 of
KRAS and exon 9 and 20 of phosphatidylinositol-4,5-bisphosphate
3-kinase PIK3CA, primers and conditions listed in Supplementary
Section 1. cDNA was synthesised from 1mg RNA by the High capacity
RNA to cDNA kit (Applied Biosystems, Foster City, CA, USA). Gene
expression of KRAS was determined using the TaqMan gene expres-
sion assay KRAS-Hs00932330_m1 (Applied Biosystems). All samples
were run on micro fluidic cards with GAPDH-Hs99999905_m1 as
endogenous control according to manufacturers instruction, and
as previously described (Krakstad et al, 2012).
Statistical analysis
Statistics were performed using the statistical programme SPSS 18.0
(Quarry Bay, Hong Kong). Associations between categorical variables
were evaluated by Pearson’s w2-test. Mann–Whitney U-test was used
for analysis of continuous variables between categories. P-values
represent two-sided tests and are considered of statistical significance
when Po0.05. Univariate analyses of time to recurrence (recurrence-
free survival) and death because of endometrial carcinoma (disease-
specific survival) were performed using the Kaplan–Meyer method.
Differences in survival were estimated by the Mantel–Cox log-rank
test.
In the statistical analysis, cutoff values were based on quartiles,
also considering the frequency distribution for each marker, the
size of subgroups and number of events in each category. Groups
with similar survival were merged.
RESULTS
Amplification of KRAS is associated with aggressive
disease and metastasis
Analysis of KRAS copy-number changes by FISH analysis showed a
large variation in KRAS/CEP12q gene probe ratio from 2 : 2 to
o20 : 2. Defining cases with a ratioX1 ando2 as gain; andX2 as
amplified in the FISH analysis, KRAS gain or amplification was
detected in 3% (13 of 414) of the primary endometrial carcinomas
investigated (Figure 1A–D). There was no significant difference
between gain and amplification of KRAS gene copy number in
terms of prognosis. Presence of KRAS gain or amplification
were highly significantly associated with traditional markers for
aggressive phenotype including high age, FIGO stage, non-
endometrioid histology, high grade, presence of lymph node
metastasis, aneuploidy and loss of hormone receptors (Table 1).
Gain or amplification of KRAS was also highly significantly
associated with poor prognosis with a 46% 5-year survival
compared with 87% for patients with unamplified status
(Po0.001) (Figure 1B). Amplification of KRAS maintains its
independent prognostic impact in Cox multivariate analysis when
adjusted for age, histological subtype, grade and FIGO stage
(HR¼ 2.6, 95% CI: 1.2–5.8, P¼ 0.02). When adjusting for adjuvant
treatment, in addition to these clinico-pathological variables,
KRAS amplification also maintained its independent prognostic
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Figure 1 Fluorescence in situ hybridisation (FISH) for KRAS copy numbers showing no KRAS amplification with CEP12 (green)/KRAS probe (red) ratio 2:2
(A); KRAS gain with KRAS/CEP12 gene probe ratio 2:3 (B); KRAS amplification with KRAS/CEP12 gene probe ratio 2:4 (C); KRAS polysomy with KRAS/CEP12
ratio 4:6 (D) and impact of copy numbers on disease-specific survival in endometrial carcinoma (E). Survival curves are estimated by the Kaplan–Meier
method with numbers of cases (events) given for cases with amplification/gain compared with unamplified cases. Proportion of cases with KRAS gene
amplification/gain increased significantly from primary (13 of 414) to metastatic (11 of 61) lesions (Po0.001, FE test) (F).
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impact in Cox’ multivariate analyses (HR¼ 2.7, 95% CI: 1.2–6.1,
P¼ 0.014). When comparing primary and metastatic endometrial
carcinoma lesions, we find a significant increase in the proportion
of samples with KRAS gain or amplification from 3% in 414
primary lesions investigated to 18% in 61 metastatic lesions
studied (Po0.001) (Figure 1C). There was no significant correla-
tion between KRAS amplification and PIK3CA mutations (Table 1).
However, KRAS amplification was highly significantly correlated to
pathological p53 expression estimated by immunohistochemistry
(Table 1). In analysis of differentially expressed genes in tumours
harbouring KRAS amplifications (n¼ 10) compared with tumours
without KRAS amplifications (n¼ 64), we find seven genes to be
significantly differentially expressed. Two genes were upregulated,
whereas five genes were downregulated as listed in Table 4.
High KRAS mRNA level reflects aggressive phenotype
To further investigate the effect of KRAS amplification on mRNA
levels, we used mRNA microarrays from 122 primary and 19
metastatic lesions, and a validation cohort analysing mRNA
expression of KRAS by qPCR in additionally 161 freshly frozen
primary endometrial carcinoma lesions. High KRAS mRNA
expression was significantly associated with high FIGO stage,
non-endometrioid histology, high grade, lymph node metastasis,
aneuploidy and hormone receptor loss (Table 2, Figure 2A and B).
The KRAS mRNA levels increased significantly from primary to
metastatic lesions (Figure 2C) and in amplified compared to
unamplified samples (estimated by SNP array, Figure 2D). In line
with this, high KRAS mRNA level was associated with poor
Table 1 Clinico-pathological variables related to KRAS gene amplification
analysed by FISH for 414 patients
Variable
Amplified,
n (%)
Not
amplified,
n (%) P-valuea
Age
p66 3 (1.3) 235 (98.7) 0.01
466 10 (5.7) 166 (94.3)
BMIb
p25 3 (2.2) 135 (97.8) 0.2
425 10 (4.5) 212 (95.5)
FIGO stagec
I–II 7 (2.0) 341 (98) 0.009
III–IV 6 (9.1) 60 (90.9)
Histological typed
Endometroid 6 (1.8) 335 (98.2) 0.003
Non-
endometroid
7 (9.6) 66 (90.4)
Gradee
Low-medium 3 (1.1) 281 (98.9) 0.002
High 10 (7.9) 117 (92.1)
Lymph nodef
Negative 5 (1.7) 298 (98.3) 0.001
Postitive 5 (13.5) 32 (86.5)
Ploidyg
Diploid 4 (1.7) 231 (98.3) 0.006
Aneuploid 5 (9.6) 47 (90.4)
ERah
Positive 5 (1.6) 306 (98.4) 0.003
Negative 8 (8.4) 87 (91.6)
PRi
Positive 3 (1) 301 (99) o0.001
Negative 9 (8.6) 96 (91.4)
PIK3CA mutj
N.m.d 7 (3.8) 177 (96.2) 0.33
Mutated 0 (0) 31 (100)
P53k
High 9 (100) 0 (0) o0.001
Low 71 (21.9) 253 (78.1)
Abbreviations: BMI¼ body mass index; ER¼ oestrogen receptor; FIGO¼ International
Federation of Gynaecology and Obstetrics; FISH¼ fluorescence in situ hybridisation;
KRAS¼Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue;
N.m.d¼ no mutations detected; PR¼ progesterone receptor. Data missing: b54, d8,
e3, f74, g127, h4, i7, j199, k81. aFisher’s exact test. cFIGO 2009 Criteria.
Table 2 Clinico-pathological variables related to KRAS gene expression
analysed by qPCR for 161 patients
Variable
High
expression,
n (%)
Low
expression,
n (%) P-value
Age
p66 20 (21.5) 74 (78.5) 0.2
466 21 (31.3) 46 (68.7)
BMIa
p25 14 (25.5) 41 (74.5) 0.7
425 27 (28.1) 69 (71.9)
FIGO stageb
I–II 28 (21.9) 100 (78.1) 0.04
III–IV 13 (39.4) 20 (60.6)
Histological type
Endometroid 25 (18.9) 107 (81.1) o0.001
Non-
endometroid
16 (55.2) 13 (44.8)
Gradec
Low-medium 17 (16) 89 (84) o0.001
High 24 (44.4) 30 (55.6)
Lymph noded
Negative 28 (22.2) 98 (78.8) 0.02
Positive 10 (52.6) 9 (47.4)
Ploidye
Diploid 19 (19) 80 (81) 0.001
Aneuploid 18 (50) 18 (50)
ERaf
Positive 21 (17) 101 (83) o0.001
Negative 19 (53) 17 (47)
PRg
Positive 20 (16) 104 (84) o0.001
Negative 19 (56) 15 (44)
PIK3CA muth
N.m.d 33 (25.6) 96 (74.4) 0.47
Mutated 6 (28.6) 15 (78.4)
P53i
High 20 (57.1) 15 (42.9) o0.001
Low 17 (16.5) 86 (83.5)
Abbreviations: BMI¼ body mass index; ER¼ oestrogen receptor; FIGO¼ International
Federation of Gynaecology and Obstetrics; KRAS¼Homo sapiens v-Ki-ras2 Kirsten rat
sarcoma viral oncogenes homologue; N.m.d¼ no mutations detected; PR¼ progesterone
receptor. The P-value was based on the w2-test or Fisher’s exact test as indicated.
Data missing: a10, c1, d16, e26, f3, g3, h11, i23. bFIGO 2009 criteria.
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prognosis in the validation cohort (n¼ 161; Figure 2E, P¼ 0.003),
and with a similar trend for the slightly smaller micro-array cohort
(n¼ 122; P¼ 0.08). In Cox multivariate analysis KRAS mRNA
expression did not maintain its prognostic significance (HR¼ 1.32,
95% CI: 0.9–2.0, P¼ 0.17) adjusted for age, histological type, grade
and FIGO stage. Presence of mutations in the PIK3CA gene was not
correlated with increased KRAS mRNA expression (Table 2). High
KRAS mRNA expression was significantly correlated to patholo-
gical p53 expression by immunohistochemistry (Table 2).
Mutations of KRAS
As KRAS mutations have been linked to response to targeted
therapy in other cancer types, and its relation to prognosis in
endometrial cancer is unsettled, we further investigated primary
and metastatic lesions for presence of KRAS mutations in DNA
extracted from freshly frozen 264 primary- and 22 metastatic
lesions. We found that 14.7% of primary tumours harboured
mutations in exon 2 of the KRAS gene. Mutations of KRAS were
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Figure 2 Box-plots showing KRAS mRNA expression levels in relation to
histological grade (A), endometrioid (E) and non-endometrioid (NE)
histological subtypes (B), primary tumours (PT) vs metastatic lesions (ML)
(C) and KRAS amplified vs unamplified status (SNP array (Salvesen et al,
2009)) (D). Estimated disease-specific survival according to expression
levels of KRAS mRNA (qPCR) according to upper quartile with number of
cases (events) given for each category.
Table 3 Clinico-pathological variables correlated to status for KRAS
mutation for 264 patients (Sanger sequencing)
Variable
KRASmutated,
n (%)
KRAS wt,
n (%) P-valuea
Age
p66 23 (16.1) 120 (83.9) 0.3
466 16 (13.2) 105 (86.8)
BMIb
p25 8 (9.8) 74 (90.2) 0.02
425 29 (20.7) 111 (79.3)
FIGO stagec
I–II 30 (13.6) 185 (86.4) 0.4
III–IV 9 (18.4) 40 (81.6)
Histological type
Endometroid 37 (17.1) 179 (82.9) 0.01
Non-
endometroid
2 (4.2) 46 (95.8)
Graded
Low-medium 31 (18.5) 137 (81.9) 0.003
High 8 (7.5) 86 (92.5)
Lymph nodee
Negative 27 (14.4) 161 (85.6) 0.45
Positive 6 (21.4) 22 (78.6)
Ploidyf
Diploid 25 (14.8) 144 (85.2) 0.5
Aneuploid 7 (13.5) 45 (86.5)
ERag
Positive 28 (15.5) 153 (84.5) 0.4
Negative 10 (17.5) 47 (82.5)
PRh
Positive 30 (16.9) 148 (83.1) 0.3
Negative 8 (15.8) 55 (87.3)
PIK3CA muti
N.m.d 31 (14.6) 181 (85.4) 0.2
Mutated 3 (8.3) 33 (91.7)
P53j
High 7 (12.7) 48 (87.3) 0.3
Low 26 (17.3) 124 (82.7)
Abbreviations: BMI¼ body mass index; ER¼ oestrogen receptor; FIGO¼
International Federation of Gynaecology and Obstetrics; KRAS¼Homo sapiens
v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue; N.m.d¼ no mutations
detected; PR¼ progesterone receptor. Data missing: c42, d2, e48, f25, g26, h23, i16,
j59. aw2-test. bFIGO 2009 criteria.
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significantly more often present in grade 1 and 2 tumours, the
endometrioid subtype and among obese patients, but no other
significant associations were seen between mutational status for
KRAS and any of the other variables investigated (Table 3). In line
with this, KRAS mutations did not influence prognosis (P¼ 0.67)
(Figure 3A). When comparing primary to metastatic endometrial
carcinoma lesions, we find no increase in the proportion of
samples with KRAS mutations. Contrasting the findings for KRAS
amplifications, patients with KRAS mutations have lower KRAS
mRNA expression than patients without KRASmutations in exon 2
(P¼ 0.035) (Figure 3B). Although not significantly anti-correlated,
only one of the 39 KRAS-mutated samples was KRAS amplified.
Interestingly, we find that only 3 of 36 patients harbouring PIK3CA
mutations had overlapping KRAS mutations (Table 3). Mutation of
KRAS was not correlated to p53 expression.
DISCUSSION
Alterations of KRAS are considered to be an important biological
factor in several cancer types (Pylayeva-Gupta et al, 2011). Over
the last decade, the main focus has been on KRAS mutation as a
predictive marker for response to EGFR inhibition (Pao et al, 2005;
Lievre et al, 2006). In colorectal- and non-small-cell lung cancers,
KRAS mutations have been reported to be associated with poor
prognosis (Rosell et al, 1993; Span et al, 1996; Fukuyama et al,
1997). Mutation of KRAS has also been linked to polypoid growth
in colorectal cancer (Chiang et al, 1998).
In endometrial cancer, it is mainly KRAS mutations that
previously have been studied in relation to clinical phenotype
(Mizuuchi et al, 1992; Ito et al, 1996; Esteller et al, 1997; Jones et al,
1997; Semczuk et al, 1998). Several studies have shown that KRAS
mutations may be present in endometrial hyperplasia’s with
atypia, presumed to be precursor lesions, suggesting mutations as
an early event in the endometrial carcinogenesis (Mutter et al,
1999). The prognostic importance of KRAS mutational status in
endometrial carcinomas has been inconsistent. Two studies
reported a 14% mutation rate with no prognostic impact
(Esteller et al, 1997; Semczuk et al, 1998), apparently in line with
our data. In contrast, Ito et al (1996) showed that 18% of 221
studied endometrial cancer patients had KRAS mutations asso-
ciated with lymph-node metastasis and poor survival among
patients above 60 years of age (Ito et al, 1996). Their reported
mutation rate is in line with our findings, but our higher frequency
amongst endometrioid grade 1 and 2 tumours, and the same
frequency of mutations detected in primary and metastatic lesions
in the present study is in contrast to their findings but more in line
with earlier studies linking KRAS mutations to early steps in
endometrial carcinogenesis (Pappa et al, 2006).
Interestingly, in the present and to date most comprehensive
study of KRAS alterations in primary and metastatic lesions from
endometrial carcinoma patients, we find that high KRAS mRNA
expression and KRAS amplification, in contrast to KRAS mutation,
are associated with a large range of surrogate markers for
unfavourable outcome and poor disease-specific survival. Appar-
ently in line with this, we find a trend towards lower KRAS mRNA
expression among KRAS-mutated cases, while samples with KRAS
amplifications have significantly higher levels of KRAS mRNA
expression and aggressive phenotype. Also the fact that mRNA
expression levels and KRAS amplification increased significantly
from primary- to metastatic lesions suggests an importance of
theses alterations later in the carcinogenic process compared with
KRAS mutations.
Of the differentially expressed genes in patients harbouring
KRAS amplifications it is interesting that upregulation of Ets2 has
been associated with poor prognosis in both pancreatic and breast
cancer (Zhang et al, 2011; McBryan et al, 2012), and down-
regulation of SOX11 have been associated with poor prognosis in
ovarian cancer (Sernbo et al, 2011). However, more research needs
to be done to elucidate KRAS-dependent gene expression
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Figure 3 Estimated disease-specific survival according to KRAS mutation status in endometrial carcinoma primary tumours with numbers of cases (events)
for each category (A). Box-plots showing KRAS mRNA expression levels by qPCR in relation to KRAS mutation status (Mann–Whitney U-test) (B).
Table 4 Genes significantly differentially expressed in patients with
amplified KRAS compared with non-amplified patients (FDR p0.05)
Gene name Description
Fold
change
Upregulated 41.5 fold
C6orf117 Chromosome 6 open reading frame 117 3.3
ETS2 V-ets erythroblastosis virus E26 oncogene
homologue 2
2.2
Downregulated 41.5 fold
LMO1 LIM domain only 1  3.8
CRTAC1 Cartilage acidic protein 1  2.5
SOX11 (Sex determining region Y)-box 11  1.8
UGT2A3 UDP glucuronosyltransferase 2 family,
polypeptide A3
 1.6
FABP1 Fatty acid-binding protein 1  1.5
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regulation in endometrial cancer, which eventually could lead to
new KRAS-targeted therapies.
To date, comprehensive genetic profiling of primary lesions
searching for potential targets for new therapeutics, have led to
only a few biomarker restricted clinical trials, of which some with
promising results (Janku et al, 2012). Still, in a setting with
systemic disease, molecular alterations in metastatic lesions may
be even more important, although so far basically unexplored for
KRAS status in endometrial cancers. Our findings support that
KRAS amplification and overexpression are more prevalent in
metastatic compared with primary lesions, and may be of
particular relevance for targeting therapies in a metastatic setting.
Our data clearly suggest that KRAS alterations are linked to
clinical phenotypes in endometrial carcinomas with increase in
copy-number and mRNA expression levels from primary to
metastatic lesions.
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Abstract
Background: Despite being the most common pelvic gynecologic malignancy in industrialized countries, no targeted
therapies are available for patients with metastatic endometrial carcinoma. In order to improve treatment, underlying
molecular characteristics of primary and metastatic disease must be explored.
Methodology/Principal Findings: We utilized the mass spectrometric-based mutation detection technology OncoMap to
define the types and frequency of point somatic mutations in endometrial cancer. 67 primary tumors, 15 metastases
corresponding to 7 of the included primary tumors and 11 endometrial cancer cell lines were screened for point mutations
in 28 known oncogenes. We found that 27 (40.3%) of 67 primary tumors harbored one or more mutations with no increase
in metastatic lesions. FGFR2, KRAS and PIK3CA were consistently the most frequently mutated genes in primary tumors,
metastatic lesions and cell lines.
Conclusions/Significance: Our results emphasize the potential for targeting FGFR2, KRAS and PIK3CA mutations in
endometrial cancer for development of novel therapeutic strategies.
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Introduction
Despite being the most common pelvic gynecologic malignancy
in industrialized countries, no targeted therapies are available for
patients with metastatic endometrial carcinoma. Although 75%
are treated at an early stage, 15% to 20% recur. For patients with
advanced disease at diagnosis or recurrent disease, outcome is
poor. In order to improve treatment, underlying molecular
characteristics of primary and metastatic disease must be explored.
Furthermore, improved tools for correct stratification of patients
according to risk-groups and improved definitions of potential
targets for novel therapeutics are of great importance and much
work is undertaken to develop better criteria to select patients for
individualized therapies [1].
To assess the risk of recurrent disease, traditionally endometrial
cancer has been divided into two subgroups, type I and type II
carcinomas [2]. Type I endometrial carcinoma is associated with
good prognosis, low grade, endometrioid histology and rarely
metastasize to regional and distant sites [3]. In addition, type I
endometrial cancers are often hormone receptor positive with
PTEN and KRAS mutations. Type II endometrial carcinomas are
associated with poor prognosis, non-endometrioid histology, high
grade, loss of hormone receptors and altered expression of p53 and
p16. Still, the value of this classification to predict prognosis and
for treatment stratification is limited as 20% of type I endometrial
cancers recur and 50% of type II cancers do not [4].
Currently, conventional chemotherapy regimens and anti-
hormonal treatment are basis for adjuvant and systemic treatment
of recurrent or metastatic endometrial cancer as targeted therapies
are not yet available in the clinic. However, mutational profiles are
applied for selection of targeted therapeutics for several other
cancers and also applied for clinical trials stratification. Our
previous screening of a smaller number of endometrial cancer
patients identified somatic mutations in FGFR2, KRAS, PIK3CA,
PTEN, PT53 and CTNNB1 [5]. However, this study did not rule
out possible mutations in other known oncogenes that could be
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e52795
potentially interesting for targeted treatment of endometrial
cancer. Thus, the current study was undertaken to screen for a
large panel of known oncogenic mutations in a series of primary
and metastatic lesions from endometrial cancer patients using the
high-throughput method OncoMap [6,7]. OncoMap provides a
unique opportunity to simultaneously interrogate a large number
of known mutations in a large number of genes, thus providing the
opportunity to characterize the molecular subgroups of endome-
trial cancer with a potential relevance for targeting novel
therapeutics.
Methods
Ethics statement
All parts of the study have been approved according to
Norwegian legislation as well as international demands for ethical
review. The study was approved by the Norwegian Data
Inspectorate, Norwegian Social Sciences Data Services, and the
Western Regional Committee for Medical and Health Research
Ethics, REC West (NSD15501; REK 052.01). Patients were
included in the study after written informed consent approved by
the ethics committee (REK West).
Specimens
We have studied a total of 69 patients for mutations in 28
known oncogenes (Table 1). 23 of the included patients had
previously been screened for fewer oncogene mutations by another
method [5]. The patients were recruited from a population based
patient series of 701 patients with endometrial cancer prospec-
tively collected at Haukeland University Hospital, Norway. Age at
diagnosis, FIGO stage, histological subtype and grade, treatment
and follow-up was registered as previously reported [8]. Distribu-
tion of clinico-pathologic variable for the 69 investigated cases did
not differ significantly from the larger (n = 701) unselected patient
cohort (Table 2). Tissue was available from 67 primary tumors and
15 metastatic lesions from 9 patients of which 7 had corresponding
tissues from primary lesions available for comparison. The
majority of selected lesions were verified by frozen sections to
contain .80% malignant epithelial component with a minimum
cut off for inclusion of 50% purity.
Cell lines
Endometrial cancer cell lines Hec1A, Hec1B, KLE, RL95-2,
ECC1 were purchased from ATCC-LGC Standards, London,
UK, MFE-280, MFE-296, MFE3-19, EFE-184, AN3-CA were
from DSMZ, Germany and Ishikawa from Sigma-Aldrich,
St.Louis, MO. All cells were maintained in medium as recom-
mended by the supplier, supplemented with Penicillin/Strepto-
mycin (Sigma-Aldrich, St.Louis, MO).
OncoMap and DNA sequencing
DNA from primary and metastatic lesions was extracted from
fresh frozen biopsies. DNA was isolated by digestion over night at
65uC in lysis buffer containing proteinase K, followed by a
standard ethanol precipitation. DNA from 11 endometrial cancer
cell lines was extracted using Qiagen Tissue DNA kit according to
manufacturers protocol. DNA quantity was measured using the
Quant-iTTM PicogreenH Assay (Invitrogen) and high quality of the
DNA assured on a 0.7% agarose gel before genomic DNA was
amplified using the Repli-g Midi Kit (Qiagen, Germany)
according to manufacturers’ instructions. Amplified DNA was
diluted 1:10 in 1xTE buffer (pH 8.0) and after hydration for 24 h
at room temperature further diluted to a working concentration of
5 ng/ml in water. Mutations were detected in genome-amplified
DNA using a mass spectrometry-based single base extension
technique (Sequenom, Inc.) as previously described [7]. Primers
for additional assays to detect mutations described in several
cancer studies since 2008 [9,10,11,12,13] were designed using the
Sequenom Assay Design Software. Following amplification and
mutation site specific probe elongation analytes were spotted on
SpectroCHIPs I and masses detected using a Bruker matrix-
assisted laser desorption/ionization–time of flight mass spectrom-
eter (Sequenom). Spectra were manually reviewed using the Typer
4.0 Software (Sequenom). A list of the mutations included in
OncoMap and the corresponding amino acid changes is given in
Table S1.
To validate the proportion of the most frequently mutated
oncogenes detected by OncoMap, genomic DNA was extracted
from freshly frozen primary tumor tissue from 199 additional
patients. In total 264 patients were screened for point mutations in
KRAS (exon 2) and PIK3CA (exon 9 and 20) as described [14].
Details regarding primers and conditions are available upon
request. Sequencing reactions were analyzed on an ABI Prism
3100 genetic analyzer using the Sequencing Analysis software,
version 3.7.
Table 1. List of genes with number of mutations (n) screened
for in OncoMap1.
Gene Mutations (n)
ABL1 13
AKT2 2
ALK 13
BRAF 29
CDK4 2
DDR2 10
EGFR 55
EPHA3 16
EPHA5 6
ERBB2 22
ERBB4 9
FGFR1 3
FGFR2 15
FGFR3 11
FGFR4 11
FLT3 5
HRAS 16
JAK2 1
KDR 8
KIT 42
KRAS 19
MDM2 1
NRAS 18
NTRK1 8
NTRK3 10
PDGFRA 20
PIK3CA 16
RET 6
1Detailed information on gene mutations and nucleotide changes is given in
Table S1.
doi:10.1371/journal.pone.0052795.t001
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Oligonucleotide DNA microarray analyses
A microarray dataset corresponding to the 69 primary tumor
samples included in the OncoMap screen was generated. RNA
was extracted using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) and hybridized to Agilent Whole Human Genome
Microarrays 44k (Cat.no. G4112F), according to the manufactur-
ers instructions. Arrays were scanned using the Agilent Microarray
Scanner Bundle and data were imported and analyzed in J-
Express software (Molmine, Norway). Median spot signal was used
as intensity measure. Expression data were normalized using
quantile normalization. Microarraydata have been deposited in
the ArrayExpress Archive database, http://www.ebi.ac.uk/
arrayexpress/ (ArrayExpress accession: E-MTAB-1358).
A SAM (Significance Analysis of Microarray) analysis between
grade I–II and grade III was performed to identify significantly
differentially expressed genes according to histologic grade. 306
genes were significantly differentially expressed (FDR,0.01)
between the two groups. Hierarchical clustering was performed
on this list of genes using weighted average linkage and Pearson
correlation as similarity measures. Clinico-pathological data and
mutational status were mapped manually to the cluster-tree to
visualize the distribution of mutation across the patient population.
Results
The OncoMap screen for 387 oncogenic mutations in 28
commonly mutated genes in cancer (Table S1) was applied in 67
primary and 15 metastatic endometrial carcinoma lesions as well
as 11 endometrial carcinoma cell lines and detected mutations in 7
of the investigated genes. We found that 27 patients (40.3%) had
point mutations in one single gene, while 4 patients (6.0%) had
mutations in 2 genes. Among the seven genes with detected
somatic mutations in primary and metastatic lesions, KRAS
(17.9%), PIK3CA (14.6%) and FGFR2 (10.4%) were the most
frequently mutated, while mutations in BRAF (1.5%), EGFR
(1.5%), HRAS (1.5%) and NRAS (1.5%) were rare. The frequencies
of KRAS and PIK3CA mutations were validated by DNA
sequencing in 264 primary tumors (Table 3). FGFR2 mutation
frequency had been validated previously [5]. The most common
single mutation found by OncoMap screening was FGFR2
aaS252W (9.0%), however the most frequently mutated gene
was KRAS (17.4%) (Table 3). The OncoMap screen of the 11
established endometrial cancer cell lines identified as expected
KRAS G12D and PIK3CA G1049R mutations in both Hec1A and
Hec1B, while FGFR2 mutation S252W was found in MFE280 and
MFE319. Additionally, two PIK3CA mutations were identified in
MFE280 and MFE296 (E545K and P539R, respectively). We did
not find any of the cell lines to have mutations in any of the other
genes included in the OncoMap panel.
To explore a possible link between type of mutations and gene
expression patterns in primary tumors, a hierarchical cluster
analysis of 306 genes significantly differentially expressed (SAM
analysis, FDR,0.01) according to histologic grade was performed.
We found that there was no significant association between specific
oncogene mutations and patient clusters based on transcriptional
signatures (Figure 1). This finding appears to be in line with our
previous report on a smaller data set applying an earlier
generation of mRNA genearrays, with no enrichment for PIK3CA
mutations in the patient cluster capturing aggressive phenotype
[15].
To further investigate if mutation pattern changed during
disease progression, 15 metastatic lesions from 9 patients from
which seven had primary tumors available for comparison, were
Table 2. Clinico-pathologic characteristics of 69 endometrial cancer patients screened in OncoMap compared to the whole
population from the same region.
Variable OncoMap n (%) Total n =69* Whole population n (%) Total n=7011
Age, median 65 65
Menopause
Pre-/Peri- 13 (19) 87 (12)
Post- 56 (81) 614 (88)
FIGO-09 stage
I–II 56 (81) 577 (82)
III–IV 13 (19) 124 (18)
Histologic type
Endometrioid 58 (84) 551 (79)
Non-endometrioid 11 (16) 150 (21)
Histologic grade
Grade 1/2 46 (68) 449 (65)
Grade 3 22 (32) 243 (35)
Metastatic nodes
Negative 38 (83) 484 (88)
Positive 8 (17) 64 (12)
ERa
Positive 49 (75) 365 (77)
Negative 16 (25) 111 (23)
*Missing (n = 69); Grade: 1, Metastatic nodes: 23, ERa: 4.
1Missing (whole population); Grade: 9, Metastatic nodes: 153, ERa: 225.
doi:10.1371/journal.pone.0052795.t002
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analyzed for mutations. KRAS, PIK3CA and FGFR2 were found to
be the most frequently mutated genes also in metastatic lesions,
with no significant increase in mutation frequency (Table 4). In
two cases, mutations were detected in the metastatic lesions but
not in the primary lesion, while one case with mutation in the
primary lesion had no detectable mutation in the metastatic lesion.
The small sample set available for this analysis, tumor heteroge-
neity and differences in stromal contamination should call for
caution in the conclusions.
Discussion
Activating mutations in specific proto-oncogenes may confer
oncogene-addiction. Such mutations have been identified in
several genes and may drive malignant disease progression. This
principal for oncogene-addiction can be exploited to develop new
targeted therapies [16]. Currently, mutational profiles are applied
for selection of targeted therapeutics for e.g. BRAF inhibitors in
malignant melanoma [17] and BRAF and EGFR targeting in
lung- and colorectal cancers [18,19]. For endometrial cancer,
none of the novel targeted therapeutics is available in the clinic at
present. However, several ongoing clinical trials aim at exploiting
Table 3. Frequency of mutations in 671 primary lesions from
endometrial cancer patients.
Gene aa OncoMap n=67
2
Validated n=264
(%)
n (%)
FGFR2 S252W 6 9
P253R 1 1.5
Total: 7 10.4 12.3 [5]3
KRAS G12C 3 4.5
G13D 3 4.5
G12D 3 4.5
G12A 1 1.5
total Exon 2 10 16.1 14.7
Q61H 2 3.0
Total: 12 17.9
PIK3CA R88Q 2 3.0
Q546K 2 3.0
E545K 2 3.0
P539R 1 1.5
total Exon 9 7 7.5 5.8
M1043I 1 1.5
H1047R 1 1.5
total Exon 20 2 3.2 8.8
Total: 9 11.9 14.6
BRAF F468C 1 1.5
EGFR T790M 1 1.5
HRAS G125 1 1.5
NRAS Q61L 1 1.5
1data missing for 2 primary tumors, n: number of mutated samples.
223 of the samples previously subjected to DNA sequencing of all exons of 89
tyrosine kinase genes and 19 additional known oncogenes and tumor
suppressor genes as reported [5].
3Validated in a dataset independent of the present study.
doi:10.1371/journal.pone.0052795.t003
Figure 1. Mutational status is not reflected in distinct patient
clusters related to phenotype. A hierarchical clustering of 306
significantly differentially expressed genes between grade I–II and
grade III was mapped with clinico-pathological data and mutational
status to visualize the distribution of mutation across the patient
population. Green square color indicate good prognosis groups (Grade
I–II, FIGO I–II, endometrioid type, ERa positivity) and no detected
mutation in indicated gene, Red square color indicate poor prognosis
groups (Grade III, FIGO III–IV, non-endometrioid types, ERa negativity)
and detected mutation in indicated gene. Black square: data missing.
doi:10.1371/journal.pone.0052795.g001
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targets supported by recent comprehensive molecular profiling of
primary endometrial carcinoma lesion [1], dominated by trials
targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mam-
malian target of rapamycin (mTOR) or FGFR2. However, to our
knowledge, no previous study has reported as comprehensive
mutational data for a large panel of oncogenes in endometrial
cancers including metastatic lesions.
A large number of oncogene mutations has been identified to be
important in cancer development. Recently, several papers have
reported the usefulness of the high-throughput genotyping
platform OncoMap to screen for mutations in a large panel of
known cancer oncogenes [6,20,21,22]. The high degree of
concordance between our findings using OncoMap for the
investigated genes and the validated frequency in the present
study as well as previously published mutation frequencies in
endometrial cancer samples based on traditional sequencing, is
assuring. Using OncoMap we found that 40.3% of the analyzed
endometrial cancer samples harbored at least one mutation. Of
the 28 oncogenes included, mutations were only found at high
frequency (.10%) in KRAS, PIK3CA and FGFR2. These genes
have been linked to endometrial cancer previously, both by us
[5,15] and others [23,24].
In the present study, the S252W mutation in FGFR2 was
identified as the most frequent single mutation (9%) in endometrial
cancer. The somatic FGFR2 mutations include the S252W and
P253R alleles, where autosomal dominant mutations are associ-
ated with the congenital developmental disorder Apert syndrome
[25]. We, and others [26], have previously linked these mutations
to endometrial cancer, through increased tumor cell survival and
anchoring independent growth in endometrial cancer cell lines,
and indicated the potential for FGFR2 inhibitors in mutated cell
lines [5]. It has also been reported that FGFR2 inhibitors induce
cell death in endometrial cancer cells despite PTEN inactivating
mutations [27]. The frequency of FGFR2 mutations detected in
the present OncoMap screen of 10.4% is in concordance with our
previous findings from 122 endometrial cancer patients from the
same region, finding FGFR2 to be mutated in 12.3% [5]. Recently,
a frequency in this range of 10.3% was also published by others
[23].
Several of the PIK3CA mutations were detected at relatively low
frequencies (,3%), however the total frequency of any detected
PIK3CA mutations was 13.4%. We have validated this frequency
of point mutations in PIK3CA (exon 9 and 20) in 14.6% in a cohort
of 264 endometrial cancer patients. This is consistent with the
reported mutational frequency of PIK3CA in endometrial carci-
noma in the COSMIC database for PIK3CA mutations tested for
in OncoMap [28]. A potential relevance for targeting therapy in
patients harboring PIK3CA mutations was recently supported in a
study demonstrating higher response rate to PI3K/AKT/mTOR
inhibitors for patients with mutated compared to wild type PIK3CA
in breast and gynecologic malignancies [29].
KRAS mutations were found in 17.9% of the cases, with high
frequency of point mutations in exon 2 (G12A, G12C, G12D and
G13D), validated in 264 endometrial cancer patients (14,7%; [14])
and also in line with previous studies (18%; [30]). KRAS mutations
have been associated with low grade, and endometrioid histologic
subtype, although not with prognosis [31,32]. Interestingly, KRAS
and FGFR2 mutations were found to be mutually exclusive, in line
with a previous report [23]. In terms of therapy KRAS mutational
status has been linked to EGFR inhibitor resistance in colorectal
cancer [33], but further studies are needed in endometrial
carcinoma to explore such potential link.
In line with the present study, we previously reported a low
frequency (2%) of mutations in BRAF in endometrial cancer [30].
Interestingly, with the exception of a few mutations in NRAS,
HRAS, EGFR and BRAF (1.5%), no other hot-spot mutations were
identified in the remaining 21 oncogenes screened for, neither in
primary tumors nor in metastatic lesions.
The present work used a version of OncoMap covering 387
mutations in a total of 28 different oncogenes. In endometrial
Table 4. Mutational status in primary endometrial cancers and corresponding metastatic lesions.
Primary Tumors Corresponding metastatic lesions
ID Gene AA Met ID Gene AA Site of met
499 n.m.d1 499a PIK3CA R88Q Spleen
394 n.m.d 394a n.m.d Vagina
1749 Data missing 1749a n.m.d Lymph node
1749b n.m.d Lymph node
1749c n.m.d Lymph node
492 Data missing 492a PIK3CA E545K Oment
492b PIK3CA E545K Gastric
279 PIK3CA P539R 279a n.m.d Oment
1393 PIK3CA R88Q 1393a PIK3CA R88Q Cervix
1406 PIK3CA FGFR2 E545K S252W 1406a FGFR2 S252W Cervix
1406b FGFR2 S252W Vagina
PIK3CA E545K
621 FGFR2 S252W 621a n.m.d Parametrium
1495 KRAS G12D 1495a KRAS G12D Vagina
1495b KRAS G12D Ovary
1495c KRAS G12D Ovary
1n.m.d: no mutation detected.
doi:10.1371/journal.pone.0052795.t004
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carcinomas, the oncogenes CTNNB1 and tumor suppressor genes
PTEN and P53 have also been reported to be frequently mutated
[34,35] but were not included in the present sceen and can
therefore not be accounted for. Among the included genes and
mutations, we have identified and validated KRAS, PIK3CA and
FGFR2 to be the most frequently mutated oncogenes in
endometrial cancer. Although transcriptional signature pattern
according to histologic grade did not identify any distinct
subgroups linking any of the mutations to phenotype, PIK3CA,
KRAS and FGFR2 mutations may still be of relevance for targeting
novel therapeutics in endometrial cancer. Nevertheless, more
knowledge regarding functional aspects of the different mutations
and their implications for response to drugs will be important to
guide further selection of patients for molecularly based clinical
trials.
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Abstract
Chromosome 8q24 is the most commonly amplified region across multiple cancer types, and the typical length of the
amplification suggests that it may target additional genes to MYC. To explore the roles of the genes most frequently
included in 8q24 amplifications, we analyzed the relation between copy number alterations and gene expression in three
sets of endometrial cancers (N = 252); and in glioblastoma, ovarian, and breast cancers profiled by TCGA. Among the genes
neighbouring MYC, expression of the bromodomain-containing gene ATAD2 was the most associated with amplification.
Bromodomain-containing genes have been implicated as mediators of MYC transcriptional function, and indeed ATAD2
expression was more closely associated with expression of genes known to be upregulated by MYC than was MYC itself.
Amplifications of 8q24, expression of genes downstream from MYC, and overexpression of ATAD2 predicted poor outcome
and increased from primary to metastatic lesions. Knockdown of ATAD2 and MYC in seven endometrial and 21 breast cancer
cell lines demonstrated that cell lines that were dependent on MYC also depended upon ATAD2. These same cell lines were
also the most sensitive to the histone deacetylase (HDAC) inhibitor Trichostatin-A, consistent with prior studies identifying
bromodomain-containing proteins as targets of inhibition by HDAC inhibitors. Our data indicate high ATAD2 expression is a
marker of aggressive endometrial cancers, and suggest specific inhibitors of ATAD2 may have therapeutic utility in these
and other MYC-dependent cancers.
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Introduction
Endometrial carcinoma is the most common pelvic gynecologic
malignancy, with a lifetime risk among women of 2–3% [1].
Approximately 75% of tumors are confined to the uterine corpus
at diagnosis and are resected. However, 15%–20% of these tumors
relapse. These tumors, and tumors that are metastatic at
presentation, respond poorly to chemotherapy or radiation and
are generally fatal [1,2].
There is a need for novel markers to identify patients with high
risk of relapse, and to develop new therapies for patients with
metastatic disease [3,4]. Unfortunately, research towards these
goals is heavily underrepresented in endometrial cancer compared
to other cancer types such as breast and ovarian cancers. One
approach is to identify genes that, when altered by somatic genetic
events, drive tumor progression. These alterations can then serve
as markers of aggressive cancers and the genes can serve as
potential therapeutic targets.
The most frequent focal amplification in endometrial cancer is
on 8q24 [5]. Indeed, 8q24 is the most commonly amplified region
across multiple cancer types [6], and this amplification is a
negative prognostic marker in several cancers [7]. Although MYC
is a likely target [6], the effects of this amplification in endometrial
cancer have never been dissected. Indeed, it is possible that it
targets multiple genes, as has been shown for amplifications
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e54873
elsewhere in the cancer genome [8]. For example, a neighboring
gene, ATAD2, has been found to be a co-regulator of MYC and
overexpression of ATAD2 has been associated with poor prognosis
in breast, lung, and prostate cancers [9,10,11].
We explore the role of the 8q24 amplification in endometrial
cancer through integrative genomic analyses of primary and
metastatic endometrial cancers with comprehensive clinical data,
and identify ATAD2 as an additional target of the 8q24
amplification in these cancers. We identify copy number gain of
ATAD2 as a regulator of ATAD2 expression, present the first data
linking ATAD2 overexpression to MYC activation, and provide
functional data suggesting ATAD2 as a therapeutic target in
MYC-dependent cancers.
Materials and Methods
Ethics Statement
The collection of endometrial carcinoma primaries and
metastases for this study was approved by the Norwegian Data
Inspectorate (961478-2), Norwegian Social Sciences Data Services
(15501) and the ‘‘Regional Research Ethics.
Committee in Medicine, Western Norway’’ (reference 052.01).
All the participants gave written informed consent.
Patient Series
Endometrial carcinoma primaries and metastases were collected
from patients treated at Haukeland University Hospital, Norway
as previously described [5]. Tumors collected for the primary
investigation and qPCR validation series were frozen immediately
upon resection; tumors collected for FISH were formalin fixed and
paraffin embedded. Patients were followed from primary surgery
until October 2010 or death. The copy-number profiles of the
primary investigation series, and the expression profiles (Agilent
21 k and 22 k oligoarrays) from a subset of 57 tumors, were
published previously [5].
RNA Analysis
RNA was extracted and hybridized to Agilent 44K arrays
(Cat.no. G4112F) according to manufacturer’s instructions and as
previously described [5]. Signal intensities were evaluated using
BRB-ArrayTools (National Cancer Institute, USA). The arrays
were batch median normalized.
Real-time Quantitative PCR
cDNA was synthesized from 1 mg RNA using High capacity
RNA to cDNA kits (Applied Biosystems). Expression of ATAD2
and MYC was determined using TaqMan gene expression assays
Hs00204205 and Hs00905030 respectively (Applied Biosystems)
and all samples were run on microfluidic cards per manufacturer’s
instructuions, using GAPDH-Hs99999905_m1 as endogenous
control. Samples were run in triplicate and analyzed in RQ
manager (Applied Biosystems).
FISH
Tissue microarrays (TMAs) representing the highest-grade areas
in each tumor were prepared as previously reported [12] and
treated at 56Cu overnight before hybridization. FISH was done
using the MYC Spectrum Orange FISH probe kit and Chromo-
some enumeration probe 8 (CEP8) (Vysis) according to manufac-
turer’s instructions, as previously reported [13]. Counting was
performed in areas of optimal tissue digestion and no overlapping
nuclei. Probe and control signals were counted in 40–60 cells
within areas of optimal tissue digestion and no overlapping nuclei.
Amplifications were scored when the MYC/CEP8 ratio was.1.0.
TCGA Validation Dataset
We accessed level 3 data from the TCGA data portal in
November and December 2010. For breast cancer we obtained
gene expression data for 279 tumors and 24 normal controls
(Agilent 244K expression arrays), and copy-number from 176
tumors (Affymetrix SNP 6.0 Arrays). For ovarian cancer we
obtained gene expression (Agilent 244K expression arrays) and
copy-number (Agilent 1M arrays) data from 514 and 489 tumors,
respectively. For glioblastoma we obtained gene expression data
from 385 tumors and 10 normal controls (Affymetrix U133A
arrays) and copy-number data from 261 tumors (Agilent 244K
arrays).
Cell Viability
Lentiviral vectors encoding shRNAs specific for ATAD2, MYC,
and the controls GFP, LACZ1, and LACZ2 (Table S1) were
obtained from The RNAi Consortium. Lentivirus was produced
by transfection of 293T cells with vectors encoding each shRNA
(5 mg) with packaging plasmids encoding PSPAX2 and PDM2.G
using Fugene HD (Roche). Lentivirus-containing supernatant was
collected 48 and 72 h after transfection, pooled, and stored at
280 uC. Cells were infected in polybrene-containing media,
centrifuged at 1,000 g for 30 min, and selected in puromycin
(2.5 mg ml21) starting 24 h after infection.
Cancer cell lines were obtained from ATCC, DSMZ, ECACC
and HSRRB, and grown according to supplier’s instructions
(Table S2). Cell viability after RNAi was measured in 96-well
plates. Eight wells seeded with cells were infected using 1:30
dilutions of virus containing each shRNA. Half of the wells
underwent puromycin selection, and cell viability was measured
using Cell-Titer Glo (Promega) one week later. The values from
each quadruplicate were averaged; ‘‘outlier’’ wells were excluded if
the replicate wells had SD/mean .0.2 and excluding the well
improved the variance. The mean ATAD2- and MYC- hairpin
values were normalized to the mean values from the GFP control.
To determine Trichostatin-A sensitivity, Trichostatin-A (Sigma)
(0.040 to 10 mM) and vehicle (DMSO) control were each added to
three wells containing each cell line on 96-well plates. Cell viability
was determined after 72 hours using Cell-Titer Glo (Promega).
Immunoblotting
Cells were washed with PBS, harvested, lysed using RIPA lysis
buffer with protease and phosphatase inhibitors, and centrifuged
at 16,0006g. Supernatant was mixed with 4X SDS sample buffer,
boiled for 7 minutes, and subjected to SDS-PAGE on 4–12%
gradient gels. Blots were probed with antibodies against ATAD2
(HPA029424, Sigma), MYC (sc-764, Santa Cruz) and actin (sc-
1615, Santa Cruz).
Statistics
Molecular data was related to clinical phenotype using
Pearson’s x2 or two-sided Student’s t test as appropriate. We
used multivariate linear regression analysis for the prediction of
ATAD2 expression levels. Univariate and multivariate survival
analyses were performed by log rank and Mantel-Cox methods,
respectively. ‘‘MYC signaling strength’’ and gene expression levels
were presented as Z-scores.
Results
Assessment of MYC as a Target of the 8q24 Amplification
Extensive biological data support MYC as an oncogene [14],
and 8q24, harboring MYC, is the most common amplified region
ATAD2 as Essential to MYC-Dependent Cancers
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across multiple cancer types [6]. However, the importance of
MYC activation in endometrial cancer is essentially unknown.
We performed an integrated analysis of copy-number and
expression data to look for evidence that MYC is a target of 8q24
amplification in endometrial cancer. We evaluated expression data
from a series of 82 endometrial cancers obtained in a single county
in Norway, with corresponding genome-wide copy-number data
from 70 tumors (the ‘‘primary investigation series’’). Sixteen of
these tumors (23%) had 8q24 amplification. Most of these
amplifications were low-level, ranging up to a copy-number of
4.7. We validated our results in four additional datasets. Two of
these represent samples with genome-wide expression profiling: an
‘‘internal validation series’’ for which we generated data from 40
primary and 19 metastatic endometrial cancers recruited from the
same region in Norway, and an ‘‘external validation series’’
representing previously published expression profiles from 111
tumors [5]. The other two validation sets represent samples
analyzed with focused assays: a ‘‘qPCR series’’ of 162 samples and
a ‘‘FISH series’’ of 399 samples. Patient characteristics and
histopathological variables for all of our internal datasets are
shown in Table S3.
We found that both MYC and genes upregulated by MYC were
overexpressed in endometrial cancers with 8q24 amplification
relative to endometrial cancers without it (p = 0.047 and
p= 0.0078, respectively) (Figures 1a–b). We used a previously
published list of 68 genes found to be upregulated by MYC across
multiple contexts and assays (Table S4; www.myccancergene.org)
[15] and scored their overexpression (‘‘MYC signaling strength’’)
using GSEA [16]. We also tested five additional MYC activation
signatures obtained from the ‘‘Gene Set Enrichment Database’’,
reflecting the activation of MYC in different contexts. Four of
these were expressed at higher levels in endometrial cancers with
8q24 amplification (Figure S1a).
However, variations in MYC expression itself only explained a
small proportion of variations in MYC signaling strength
(R2= 0.11, p= 0.002) (Figure S1b). We obtained similarly weak
results in the internal and external validation datasets (R2= 0.00,
p = 0.34 and R2=0.06, p = 0.012, respectively; Figure S1b).
Across all three datasets, variations in MYC expression only
account for 5% of variations in MYC signaling strength
(R2= 0.05, Figure 1c).
Moreover, 8q24 amplifications are longer than the typical
distribution of amplification sizes in endometrial cancer
(p = 0.0021) (Figure 1c), and usually involve multiple genes. We
therefore hypothesized that 8q24 amplifications may target
additional genes, some of which may function through increasing
MYC signaling. To identify these, we evaluated all 26 genes in the
peak region of amplification on 8q24 for which we had expression
data, to identify genes whose expression correlated most strongly
with amplification.
Expression of ATAD2 Correlates Strongly with 8q24
Amplification and MYC Signaling
Expression of ATAD2 was more strongly associated with
amplification of 8q24 than was expression of any other gene in
the peak region of the amplification (p-value = 2.77E-06)
(Figure 1d). Four other genes, NDUFB9, DERL1, FAM91A1, and
WDR67, were significantly upregulated by 8q24 amplification,
though less strongly than ATAD2.
Expression of ATAD2 also correlated with MYC signaling
strength more strongly than did expression of any other gene in
the 8q24 peak region (R2= 0.48, p,0.001; Figure 1e, Figure S1b).
Indeed, the association between ATAD2 expression and MYC
signaling strength was observed even among samples without 8q24
amplification (R2=0.48, p,0.001). The correlation between
ATAD2 expression and MYC signaling strength was more than
twice as strong as the next most significantly associated gene
(NDUFB9) and stronger than for MYC itself (R2= 0.05; Figure 1c).
ATAD2 is not one of the 68 genes in the MYC activation signature,
and to our knowledge MYC has not been found to modulate
expression of ATAD2 [15]. However, ATAD2 was previously
found to bind to MYC and to the E-box region of several MYC
target genes, and ATAD2 levels were found to be limiting for
MYC-dependent transcription [9].
Both genome-wide validation series also exhibited the correla-
tion between MYC signaling and ATAD2 expression (R2=0.54,
p,0.001 and R2= 0.45, p,0.001 in the internal and external
validation series, respectively) and the relative lack of correlation
with MYC expression (R2= 0.00, p = 0.33 and R2=0.06,
p = 0.012; Figures 1f and S1b). Expression of ATAD2 also
correlated with four of the five additional signatures of MYC
activation, and correlated more strongly with these signatures than
did expression of MYC itself (Table 1). The last signature showed
no association with ATAD2 or MYC expression.
Amplification of 8q24 and Expression of ATAD2, but not
MYC, are Associated with Disease Progression
Among the 70 endometrial cancers for which we had genome-
wide SNP array data, 8q24 amplification was associated with
reduced progression-free survival (p = 0.024) and increased risk for
disease-specific death (p = 0.043). Amplification of 8q24 was most
frequent in non-endometrioid (p = 2.98E-05) and high-grade
tumors (p = 2.90E-08) (Table S5), features also associated with
aggressive cancers [17].
We confirmed 8q24 amplification is associated with poor
prognosis using FISH in an independent series of 399 endometrial
cancers. Twenty cancers (5%) exhibited increased 8q24 copy-
numbers relative to the chromosome 8 centromere (Figure 2a).
These were associated with 64% 5-year survival, vs. 85% for
cancers without 8q24 amplification (p,0.001) (Figure 2b). A
similar pattern was seen for recurrence free survival (p = 0.001).
Amplification of 8q24 was also associated with high FIGO stage
(p = 0.003), non-endometrioid histological subtype (p,0.001), and
high grade (p,0.001) (Table S5).
High expression of ATAD2 and MYC signaling were also
associated with increased risk of cancer progression (p= 0.003 and
p= 0.015, respectively), cancer-specific death (p= 0.004 and
p= 0.001) (Figures 2c–d), and other poor-prognosis features.
ATAD2 expression was higher in non-endometrioid, high-grade
and ER negative tumors (p,0.001, p,0.001, and p= 0.02
respectively; Table S6); high MYC signaling was associated with
poorly differentiated (p = 0.0016) and non-endometrioid
(p,0.001) cancers. Expression of ATAD2 was also negatively
associated with expression of ESR1 (R2= 0.10, p = 0.005).
Similarly, prior studies have found that ATAD2 expression is
higher in triple negative breast cancer tumors [18] and is
downregulated by estrogen in cell culture [19].
Indeed, ATAD2 expression was an independent predictor for
disease-specific death (HR=1.83, p = 0.027) and disease progres-
sion (HR=1.62, p = 0.011) after adjusting for ER status. ER-
negative tumors with upper-quartile ATAD2 expression were
particularly lethal (HR=4.1, p = 0.002; Figure 2e).
We confirmed these results by assessing ATAD2 expression by
quantitative PCR and ER status by immunohistochemistry in our
qPCR validation series of 162 additional tumors. Among these,
ER-negative tumors with upper-quartile ATAD2 expression were
associated with even worse outcomes than in the primary series
(HR=6.8, p,0.001) (Figure S1c). High ATAD2 expression also
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remained associated with increased risk of disease-specific death
(p = 0.0043) and shorter progression-free survival (p = 0.016). After
adjusting for ER status, ATAD2 expression continued to predict
disease-specific death (HR=1.86, p= 0.018) but only trended
towards an association with disease progression (HR=1.31,
p = 0.11). Expression of ATAD2 was also higher in high-grade
(p,0.001), non-endometrioid (p = 0.005), and ER-negative tumors
(p = 0.02) (Table S6).
In contrast,MYC expression was not associated with progression
or risk of disease-specific death in either our primary investigation
series (p = 0.07 and p=0.68 respectively) or the qPCR validation
series (p = 0.53 and p=0.28 respectively). High expression ofMYC
was associated with high grade in both series (p,0.001 and
p= 0.02, respectively), and with non-endometrioid histology in the
primary investigation series (p = 0.03) (Table S6).
Metastases also exhibit more 8q24 amplification, ATAD2
expression, and MYC signaling strength than primary tumors.
Relative to primary tumors, metastases exhibited 2.46higher rates
of focal 8q24 amplification by FISH (14.3%; p,0.007). Among
the 399 patients in the FISH series, 49 had paired primary and
metastatic tumors. Five of these samples (10%) did not exhibit
8q24 amplification in the primary but acquired it in the metastasis.
Only one sample (2%) exhibited the opposite pattern. To examine
ATAD2 expression and MYC signaling, we also compared the 42
primary tumors with the 19 metastases in our internal validation
series. Both ATAD2 expression and MYC signaling strength were
higher in the metastases (p = 0.002 and 0.004 respectively;
Figure 2f–g), including among 8 patients with paired primary
tumors and metastases (p = 0.01 and 0.05 respectively).
Extension to Other Cancer Types and Normal Tissue
We also investigated whether 8q24 amplification is associated
with increased ATAD2 expression in other cancer types. Specif-
ically, we used data from 514 ovarian cancers, 279 breast cancers,
and 385 glioblastomas from The Cancer Genome Atlas [20,21].
These included expression data from adjacent normal tissue for 24
breast cancers and 10 glioblastomas. 8q24 amplifications were
observed in 72% (N=126) of the breast cancers, 74% (N=364) of
the ovarian cancers, and 10% (N=27) of the glioblastomas.
ATAD2 was co-amplified to the same level as MYC in nearly all
tumors (as it was among our endometrial cancers; Figure S1d–g).
Expression of ATAD2 correlated with 8q24 amplification among
all three cancer types (R2= 0.47, 0.11, and 0.36 for breast cancers,
glioblastomas, and ovarian cancers respectively; p,0.001 in all
cases; Table S7), and was 2.66 and 2.56 higher among the
cancers relative to normal tissue in breast cancer and glioblastoma,
respectively (p,0.001 in both cases). MYC expression correlated
less strongly with 8q24 amplification in all three cancer types
(R2= 0.12, 0.07, and 0.10 for breast cancers, glioblastomas, and
ovarian cancers respectively; p,0.001 in all cases). MYC
expression in breast cancers was surprisingly half that of normal
tissue (p,0.001); in glioblastoma it was higher by a factor of 3.5
(p,0.001).
ATAD2 expression also correlated with MYC signaling in all
three cancer types (R2= 0.11, 0.21, and R2=0.31, respectively for
Figure 1. MYC, ATAD2 and 8q24 associations. (a) MYC expression and (b) MYC signaling are both increased among endometrial cancers with
8q24 amplification. (c) Variations in MYC expression only explain a small proportion of the variation in MYC signaling. Linear fits are shown in red,
yellow, and green for the primary investigation series, internal validation series, and external validation series, respectively. (d) The lengths of the
amplifications that contain MYC are significantly larger than expected compared to amplifications observed elsewhere in these cancers. (e) Among 26
genes in the 8q24 peak with corresponding expression data, expression of ATAD2 is most strongly and significantly associated with amplification.
Blue bars show the percent increase in gene expression and red bars show the p-values. The significance threshold is Bonferroni-corrected for
multiple hypotheses. (f) Expression of ATAD2 is highly correlated with MYC signaling strength. Linear fits are shown as in panel c.
doi:10.1371/journal.pone.0054873.g001
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breast cancers, glioblastomas, and ovarian cancers; p,0.001 in all
cases), and was more strongly correlated with MYC signaling
strength than MYC expression was (R2= 0.10, p,0.001;
R2= 0.09, p,0.001; and R2=0.02, p = 0.003 in the three cancer
types).
ATAD2 Expression is Correlated to E2F Gene Expression
and ATAD2 Copy Number in an Additive Manner
We also explored the relative contributions of E2F, estrogen,
and copy-number on ATAD2 expression. The ATAD2 promoter
region contains binding sites for several E2F proteins and previous
functional data have shown that E2F increases ATAD2 expression
in cell culture [9,22]; ATAD2 has also been induced by estrogen
[23]. In our data, expression of every E2F transcription factor was
associated with ATAD2 expression, but only the inclusion of E2F1,
E2F2 and E2F8 improved the overall fit of a model predicting
ATAD2 expression from ATAD2 copy-number and ESR1 expres-
sion. The expression levels of these three genes were highly
correlated, and we focused on E2F1.
We found that ATAD2 copy-number, ESR1 expression and
E2F1 expression explained 77% of the variation in ATAD2
expression in endometrial cancer, and each of the predictor
variables remained significantly associated with ATAD2 expression
in the adjusted model (Figure 3a and Table S7). We also found
that ATAD2 copy-number and E2F expression independently
predicted ATAD2 expression in breast cancer, ovarian cancer and
glioblastoma (Figure 3b–d and Table S7). ESR1, which was less
strongly associated with ATAD2 expression, was significant in the
adjusted model only in endometrial cancer (p = 0.016) and
glioblastoma (p,0.001), not in ovarian or breast cancer. These
data suggest that the copy-number of ATAD2 is an important
determinant of ATAD2 expression even in the context of other
cellular regulatory mechanisms.
Dependency on MYC Predicts Dependency on ATAD2
and Response to HDAC Inhibitors in Endometrial- and
Breast Cancer Cells
The results above led us to hypothesize that ATAD2 expression
promotes MYC signaling and that endometrial cancer cells that
are dependent upon MYC would also be dependent upon ATAD2.
We measured the effect on viability of shRNA knockdowns of
ATAD2 and MYC in seven endometrial cancer cell lines. We used
two shRNAs against each gene, selecting those that exhibited the
greatest reduction of protein expression among six and three
shRNAs screened against ATAD2 andMYC respectively (Figure 4a,
b).
Knockdown of either ATAD2 or MYC resulted in highly
correlated decreases in viability across the seven cell endometrial
cancer lines (R2= 0.70, p = 0.020; Figure 4c). In two cases, we
observed over 75% reductions in viability. We found no
Table 1. Associations between other MYC activation gene sets and ATAD2- and MYC expression.
ATAD2 MYC
Gene set R2 P-value P-value* R2 P-value P-value*
Schumacher myc up{ 0.45 ,0.001 ,0.001 0.11 ,0.001 0.001
Primary Investigation Series 0.43 ,0.001 ,0.001 0.16 ,0.001 0.025
Internal validation Series 0.38 ,0.001 ,0.001 0.05 0.800 0.252
External validation Series 0.5 ,0.001 ,0.001 0.49 ,0.001 0.026
Coller myc up{ 0.35 ,0.001 ,0.001 0.10 ,0.001 0.002
Primary Investigation Series 0.36 ,0.001 ,0.001 0.19 ,0.001 0.006
Internal validation Series 0.22 ,0.001 0.001 0.03 0.186 0.427
External validation Series 0.43 ,0.001 ,0.001 0.10 0.001 0.08
Yu cmyc up1 0.62 ,0.001 ,0.001 0.05 ,0.001 0.987
Primary Investigation Series 0.62 ,0.001 ,0.001 0.06 0.290 0.612
Internal validation Series 0.68 ,0.001 ,0.001 0.02 0.252 0.973
External validation Series 0.60 ,0.001 ,0.001 0.07 0.006 0.632
Myc oncogenic signature" 0.20 ,0.001 ,0.001 0.23 ,0.001 ,0.001
Primary Investigation Series 0.27 ,0.001 ,0.001 0.19 ,0.001 0.004
Internal validation Series 0.08 0.042 ,0.001 0.32 ,0.001 0.133
External validation Series 0.24 ,0.001 ,0.001 0.22 ,0.001 ,0.001
Lee myc up|| 0.05 ,0.001 0.001 0.02 0.150 0.147
Primary Investigation Series 0.02 0.175 0.175 0.00 0.825 0.79
Internal validation Series 0.00 0.656 0.587 0.00 0.612 0.553
External validation Series 0.18 ,0.001 ,0.001 0.18 0.002 0.051
R2 and p-values are derived from a linear regression of the sum of expression values within the gene set against ATAD2 or MYC expression.
*Adjusted for ATAD2 or MYC expression.
{Genes up-regulated in P493-6 cells (Burkitt’s lymphoma) induced to express MYC (Schumacher).
{Genes regulated by forced expression of MYC in 293T (transformed fetal renal cell).
1Genes up-regulated in B cell lymphoma tumors expressing an activated form of MYC.
"Genes selected in supervised analyses to discriminate cells expressing c-Myc from control cells expressing GFP. Myc oncogeneic.
||Genes up-regulated in hepatocellular carcinoma (HCC) induced by overexpression of MYC.
doi:10.1371/journal.pone.0054873.t001
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association between expression of ATAD2 or MYC or 8q24 copy
number and sensitivity to ATAD2 or MYC knockdown.
These results suggested that MYC-dependent cancers of other
types might also be dependent on ATAD2. No decrease in
proliferation had previously been seen with ATAD2 knockdown in
TIG3-T or U2OS cells [9]. When we tested a larger panel of 21
breast cancer lines, however, we confirmed the strong correlation
between decrease in viability after knockdown of ATAD2 or MYC
(R2= 0.61, p,0.001; Figure 4d).
The association between dependency on MYC and ATAD2
suggests ATAD2 as a therapeutic target in MYC-dependent
cancers. Whereas MYC has long been a known oncogene, clinical
approaches to block MYC signaling have not yet been successful.
Histone deacetylase (HDAC) inhibitors, however, have been
shown to indirectly inhibit bromodomain-containing proteins such
as ATAD2 [24].
We used the Connectivity Map [25] to identify compounds
whose signatures anticorrelated with the MYC signaling signature.
Among the 1309 small molecules represented by the Connectivity
Map, the signature of the HDAC inhibitor Trichostatin-A was
most anticorrelated with the MYC signaling signature. (p-
value,0.00001; Table S8). We also generated a signature of
aggressive disease from the primary investigation series, using the
50 most over- and under-expressed genes in patients with
metastatic disease compared to patients without metastatic disease.
We found the Trichostatin-A signature was also the most
anticorrelated with this signature of aggressive disease, tied with
signatures of four other molecules (p,0.00001; Table S8).
To functionally confirm the relation between Trichostatin-A
and MYC dependency, we tested all endometrial cancer and
Figure 2. Amplification of 8q24, ATAD2 overexpression and increasedMYC signaling are associated with poor prognosis. FISH probes
against 8q24 (red) and the chromosome 8 centromere (green) in a primary tumor and the paired metastasis show amplification only in the latter (a)
(b) Among 399 patients assessed by FISH, those with 8q24 amplifications have worse outcome. In the primary investigation series, tumors among the
highest quartiles of (c) ATAD2 expression and (d) MYC signaling strength also had increased risk of disease-specific death. (e) Estrogen receptor
negative (ER2) tumors with ATAD2 expression in the top quartile were also associated with a high risk of disease-specific death; the risk was much
lower among estrogen receptor positive (ER+) tumors with ATAD2 expression in the bottom quartile. (f) ATAD2 expression and (g) MYC signaling are
both higher among metastases than primary tumors in the internal validation series.
doi:10.1371/journal.pone.0054873.g002
Figure 3. 3-D-plots showing ATAD2 expression and -copy-
number and E2F1 expression. (a) Endometrial cancer, (b) breast
cancer, (c) ovarian cancer, and (d) glioblastoma. Yellow dots represent
the samples and the blue plate is the predicted 3-D fit. The green and
red lines are the distance between the predicted fit and the actual
observations for samples above and below the 3D-fit plate, respectively.
doi:10.1371/journal.pone.0054873.g003
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breast cancer cell lines for growth inhibition by Trichostatin-A and
compared the results toMYC knockdown. Trichostatin-A inhibited
growth in the same cell lines which were dependent on MYC both
in the endometrial (R2= 0.74, p= 0.013; Figure 4e), and in the
breast cancer cell lines (R2= 0.31, p= 0.007; Figure 4f) but the
overall efficacy of Trichostatin-A at reducing cell viability was
lower among the doses we tested (0.04–10 mM) (Table S9) than
were the effects of MYC or ATAD2 knockdown.
Discussion
Our data suggest that ATAD2 overexpression in human
endometrial cancers is a consequence of 8q24 amplification and
associated with MYC pathway activation. We also find that
ATAD2 overexpression is associated with E2F activation and poor
prognosis. Analyses of TCGA data suggest similar relationships
between ATAD2, 8q24 amplification, and MYC pathway activa-
tion in glioblastoma, breast, and ovarian cancers. We also find that
endometrial and breast cancer cell lines that are dependent upon
MYC expression also depend upon expression of ATAD2.
High expression of ATAD2 has previously been found to be
associated with an unfavorable prognosis in breast, lung, and
prostate cancers and it has been suggested that ATAD2
contributes to the development of aggressive cancer through
linking of the E2F and MYC pathways [9,10,11]. We demonstrate
an association between high ATAD2 expression and negative
outcome in endometrial cancer, using clinically well-characterized
test and validation datasets. We also find that progression from
primary to metastatic endometrial cancer is associated with a
further increase of MYC signaling and ATAD2 expression.
Ciro et al [9] previously showed that ATAD2 interacts with
MYC in breast cancer cell lines and is overexpressed in 8q24
Figure 4. Correlation between effects of ATAD2 and MYC knockdown. Western blots for (a) ATAD2 and (b) MYC indicate extent of
knockdown with six shRNAs against ATAD2 and three shRNAs against MYC, respectively. ATAD2 experiments were performed in KLE cells and MYC
experiments were performed in TE9 cells infected with GFP control and MYC vectors. Subsequent experiments used ATAD2 shRNAs a and e, and MYC
shRNAs a and b. Reductions in cell viability among seven endometrial cancer cell lines (c) and 21 breast cancer cell lines (d) were highly correlated
after knockdown of ATAD2 or MYC and after knockdown of MYC and treatment with the HDAC inhibitor Trichostatin-A (1.25 mM) (e–f).
doi:10.1371/journal.pone.0054873.g004
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amplified breast cancers. Our results indicate that, in endometrial
cancers, expression of ATAD2 is more highly correlated with 8q24
amplification than is expression of its neighbors (including MYC),
and that ATAD2 amplification and overexpression are strongly
associated with multiple measures of MYC pathway activation in
human tumors.
The finding of cooperative effects between MYC and coampli-
fied genes on 8q24 is not entirely surprising. Indeed, the concept of
oncogene cooperation was established through the study of
positive interactions between MYC and other oncogenes such as
BCL2 [26]. Moreover, clustered genes are often functionally
related [27]. The relevance of this phenomenon in cancer has
been shown for the genes MMP13, Birch2, and Birch3, which are
functionally related oncogenes contained on the same amplifica-
tion in osteosarcoma [28], and for BIRC2 and YAP1, cooperating
oncogenes in an amplification in hepatocellular carcinomas [8].
Such a mechanistic association between ATAD2 and MYC, and
the finding that MYC-dependent cells are sensitive to ATAD2
knockdown, suggest ATAD2 as a therapeutic target in MYC-
dependent cancers. Although MYC has long been known as an
oncogene [14] and is a promising drug target, it has not been
successfully targeted therapeutically. Small molecule inhibitors
have, however, been generated against other bromodomain-
containing proteins [29]. Indeed, inhibition of the bromodomain-
containing protein BRD4 has recently been suggested as an
alternative approach to targeting MYC [30]. HDAC inhibitors
also indirectly inhibit bromodomain-containing proteins by
inducing histone hyperacetylation, thus probably diverting the
specific bromodomain proteins from their targets [24]. This may
account for some of the effectiveness of HDAC inhibitors as cancer
therapeutics [30], and we found cell lines that were sensitive to
knockdown of MYC or ATAD2 were also sensitive to the HDAC
inhibitor Trichostatin-A. However, the reduction in viability after
application of Trichostatin-A was smaller than the reduction in
viability after MYC or ATAD2 knockdown. It is possible that a
more direct inhibitor of ATAD2 would be more effective in these
cells.
Major obstacles to treatment of patients with endometrial
cancer include a lack of targeted therapeutics and of prognostic
indicators. Indeed, endometrial cancer remains understudied
relative to other cancer types. We find that ATAD2 amplification
and expression is a prognostic marker in endometrial cancer and
our findings suggest that development of specific ATAD2
inhibitors is a promising approach to treatment of endometrial
and other MYC driven cancers.
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